

**UNITED STATES SENATE
COMMITTEE ON THE JUDICIARY**

QUESTIONNAIRE FOR NON-JUDICIAL NOMINEES

PUBLIC

1. **Name:** State full name (include any former names used).

**Andrew Thomas McLellan; A. Thomas McLellan;
Thomas McLellan; Tom McLellan**

2. **Position:** State the position for which you have been nominated.

Deputy Director, Office of National Drug Control Policy

3. **Address:** List current office address. If city and state of residence differs from your place of employment, please list the city and state where you currently reside.

**Treatment Research Institute
600 Public Ledger Building
150 S. Independence Mall (west)
Philadelphia, PA 19106**

4. **Birthplace:** State date and place of birth.

**May 29, 1948
New York City, New York
U.S.A.**

5. **Education:** List in reverse chronological order each college, law school, or any other institution of higher education attended and indicate for each the dates of attendance, whether a degree was received, and the date each degree was received.

**1972-1976 Bryn Mawr College – PhD, Experimental Psychology, 1976
1971 Trinity College, Oxford University – Special Study Group Psychology
1966-1970 Colgate University – BA, dual major (Psychology and Biology), 1970**

6. **Employment Record:** List in reverse chronological order all governmental agencies, business or professional corporations, companies, firms, or other enterprises, partnerships, institutions or organizations, non-profit or otherwise, with which you have been affiliated as an officer, director, partner, proprietor, or employee since graduation from college, whether or not you received payment for your services. Include the name and address of the employer and job title or description.

Professional Employment History

1992 to present

Treatment Research Institute (non profit research org.) – CEO

600 Public Ledger Building

150 S. Independence Mall (west)

Philadelphia, PA 19106

1978 to present

University of Pennsylvania – Professor of Psychiatry

3400 Spruce St.

Philadelphia, PA 19104

1994 – 2000

DeltaMetrics (for- profit research org.) – Scientific Director

600 Public Ledger Building (Shared offices with Treatment Res. Inst.)

150 S. Independence Mall (west)

Philadelphia, PA 19106

1975 – 2002

Veterans Administration – Research Psychologist

3900 University Avenue

Philadelphia, PA 19104

Pro Bono Work

1995 Member, US-China Drug Research Task Force, Beijing

1995 Science Policy Board Member, National Institute on Drug Abuse

**1995 - 2003 Member, National Advisory Council, National Institute on Drug Abuse
Chair, NIDA Council Steering Committee 2001 - 2003**

1995 - 2006 Drug Policy Advisor, National Football League

1996 Advisor National Academy of Science, Institute of Medicine

1997 - 2001 Associate Editor, Alcoholism: Clinical and Experimental Research

1997 Committee Member, National Academy of Science, Institute of Medicine

1997 - 2001 Advisor, Office of National Drug Control Policy, Research and Evaluation

1998 - 2002 Associate Editor, Journal of Studies on Alcohol

1998 Advisor, Physician Leadership on National Drug Policy

1998 Advisor, Swiss National Science Foundation, Bern, Switzerland

1999 Advisor, World Health Organization

1999 Extramural Member, NIAAA Panel for Review of Research Portfolio

2000-2009 Editor in Chief, Journal of Substance Abuse Treatment

2000-2001 CSAT National Treatment Plan – Section Chair

**2000-2009 Advisor to government of Greece on drug abuse treatment/Advisor on
Evaluation, KETHEA, Inc., of Greece**

2004 Member, NIAAA Treatment Research Internal Review Group

**2004 Member, National Academy of Sciences, Institute of Medicine Panel,
“Crossing the Quality Chasm in Behavioral Health Treatment”**

2000	United Nations Office of Public Health, Project Director – “Investing in Drug Abuse Treatment”
2004	World Health Organization Committee on Essential Medicines – Methadone
2006	National Quality Forum Steering Committee. Evidence-Based Practices to Treat Substance Use Conditions
2007	Scientific Director, HBO Documentary Films “Addiction”
2007	Member DSM V - Committee - Revising diagnostic criteria for Substance Use Disorders

7. **Military Service and Draft Status:** Identify any service in the U.S. Military, including dates of service, branch of service, rank or rate, serial number (if different from social security number) and type of discharge received, and whether you have registered for selective service.

**1971 – 1976 US Army Reserve
157th Infantry Brigade
Honorable Discharge**

8. **Honors and Awards:** List any scholarships, fellowships, honorary degrees, academic or professional honors, honorary society memberships, military awards, and any other special recognition for outstanding service or achievement.

2001	Life Achievement Award – British Society of Addiction Medicine
2002	Distinguished Contribution (In Addiction Medicine) Swedish Medical Association
2002	Significant Contribution Award – Italian Society of Addiction Medicine – Milan, Italy
2003	Thomas Okey Honorary Lecture – British Medical Society
2003	Lifetime Achievement Award - American Society of Addiction Medicine
2003	Institute for Scientific Information, most “Highly Cited Researcher” in psychology/psychiatry 1980 - 2000
2003	Robert Wood Johnson Foundation, Innovator Award
2003	First Recipient – Johns Hopkins University Innovators Award lecture
2004	Lifetime Service Award, National Association of State Alcohol and Drug Abuse Directors
2004	Owens Award and Lecture, University of Georgia
2005	Distinguished Research Scholar Award – American Journal on Addictions
2006	McGovern Award Association for Medical Education and Research in Substance Abuse
2007	Distinguished Achievement Award, Institute for Behavioral Health
2007	Marian Fischman Lecture - Columbia University, New York.
2008	Louis DeLaparte Distinguished Lecture. University of South Florida.

9. **Bar Associations:** List all bar associations or legal or judicial-related committees, selection panels or conferences of which you are or have been a member, and give the titles and dates of any offices which you have held in such groups.

Not Applicable

10. **Bar and Court Admission:**

- a. List the date(s) you were admitted to the bar of any state and any lapses in membership. Please explain the reason for any lapse in membership.

Not Applicable

- b. List all courts in which you have been admitted to practice, including dates of admission and any lapses in membership. Please explain the reason for any lapse in membership. Give the same information for administrative bodies that require special admission to practice.

Not Applicable

11. **Memberships:**

- a. List all professional, business, fraternal, scholarly, civic, charitable, or other organizations, other than those listed in response to Questions 9 or 10 to which you belong, or to which you have belonged, since graduation from law school. Provide dates of membership or participation, and indicate any office you held. Include clubs, working groups, advisory or editorial boards, panels, committees, conferences, or publications.

1976 – 2009 Member of the Board of Directors: College on Problems of Drug Dependence

This is a professional research society that holds an annual research meeting and publishes a journal (Drug and Alcohol Dependence)

1995 - 2000 Member of the Board of Directors, Johnson Institute Foundation

1998 – 2007 Member, American College on Neuropsychopharmacology

This is also a professional research society that holds an annual research meeting and publishes a journal (Neuropsychopharmacology)

1999 – 2000 Member, Research Society on Alcoholism

This is also a professional research society that holds an annual research meeting and publishes a journal (Alcoholism)

2005 Board of Directors Member – Drug Strategies Inc.

2009 President, College on Problems of Drug Dependence

2007- 2009 Member of the Board of Directors for the Partnership for a Drug Free America

- b. Indicate whether any of these organizations listed in response to 11a above currently discriminate or formerly discriminated on the basis of race, sex, religion or national origin

No, membership is based only on research interests and expertise.

12. Published Writings and Public Statements:

- a. List the titles, publishers, and dates of books, articles, reports, letters to the editor, editorial pieces, or other published material you have written or edited, including material published only on the Internet. Supply four (4) copies of all published material to the Committee.

BOOKS: note: copies of these are at TAB A

1. Addiction Research and Treatment: Converging Trends, by E. Gottheil, A. T. McLellan, and K.A. Druley (editors) Pergamon Press, N.Y., 1979.
2. Matching Patient Needs and Treatment Methods in Alcohol and Drug Abuse, by E. Gottheil, A.T. McLellan, K.A. Druley (eds.) Charles Thomas Pub., Chicago, 1981.
3. McLellan A.T., Bragg A., and Cacciola J., Escape From Anxiety and Stress, Chelsea House Pub., New York, 1985.
4. McLellan A.T., Investing in Drug Abuse Treatment: A Discussion Paper for Policy Makers. United Nations International Drug Control Programme. United Nations Press. N.Y., N.Y., 2001.
5. Volpicelli J.R., Pettinati H.M., McLellan A.T. and O'Brien C.P., Combining Medication and Psychosocial Treatments for Addictions: The BRENDA Approach. Guilford Press, NY, NY, 2001.

Unable to Provide:

1. Substance Abuse and Psychiatric Illness, by E. Gottheil, A.T. McLellan, and K.A. Druley (eds.), Pergamon-Maxwell, N.Y., 1980.

RESEARCH PUBLICATIONS, PEER REVIEWED:

Note: copies of these articles are at TAB B-1

1. McLellan, A.T., Druley, K.A.: A comparative study of response to treatment in court-referred and voluntary drug patients. Hospital and Community Psychiatry, 28: 241-249, 1977.
2. McLellan, A.T., Druley, K.A.: The readmitted drug patient: Evidence of failure or gradual success? Hospital and Community Psychiatry, 28:764-766, 1978.

3. McLellan, A.T., Druley, K.A., Carson, J.E.: Evaluation of substance abuse problems in a psychiatric hospital. Journal of Clinical Psychiatry, 39(5):425-430, 1977.
4. McLellan, A.T., Luborsky, L.: Our surprising inability to predict the outcomes of psychological treatments- with special reference to treatments for drug abuse. American Journal of Drug and Alcohol Abuse, 5(4):387-398, 1978.
5. McLellan, A.T., Hery, D.S., Druley, K.A.: Staff drinking patterns and approach to patient drinking problems within a psychiatric hospital. American Journal of Drug and Alcohol Abuse, 5(4): 507-516, 1978.
6. McLellan, A.T., Woody, G.E. O'Brien, C.P. Development of psychiatric illness in drug abusers. New England. Journal of Medicine, 301:1310-1314, 1979.
7. McLellan, A.T., MacGahan, J., Druley, K.A.: Changes in drug abuse clients 1972-1978: Implications for revised treatment. American Journal of Drug and Alcohol Abuse, 6(2):151-162, 1979.
8. Alterman A.I., Erdlen F.R., McLellan A.T., Mann S.T. Problem drinking in hospitalized schizophrenic patients. Addictive Behaviors, Vol. 5, 273-276, 1980.
9. Krieger, E., McLellan, A.T., Parente, R. Opening move in substance abuse therapy: Appropriateness of treatment assignment. American Journal of Drug and Alcohol Abuse, 7(3&4): 347-359, 1980.
10. Marcovici, M., McLellan, A.T., O'Brien, C.P., Rosenzweig, J.: Risk for alcoholism and methadone treatment: A longitudinal study. Journal of Nervous & Mental. Disease, 168: 556-558, 1980.
11. McLellan, A.T., Druley, K.A., O'Brien, C.P., Kron, R., Alterman, A.I.: Matching substance abuse patients to appropriate treatments: A conceptual and methodological approach. Drug and Alcohol Dependence, 5(1980): 189-195, 1980.
12. McLellan, A.T., Luborsky, L., O'Brien, C.P., Woody, G.E.: An improved diagnostic evaluation instrument for substance abuse patients: The Addiction Severity Index. Journal of Nervous & Mental Disease, 168(1): 26-33, 1980.
13. McLellan, A.T., O'Brien, C.P. Luborsky, L., Woody, G.E., Kron, R. Are the "addiction-related" problems of substance abusers really related? Journal of Nervous and Mental Disease, 169(4)232-239, 1981.
14. Alterman, A. & McLellan, A.T.: A framework for refining the diagnostic categorization of substance abusers. Addictive Behaviors, 6: 23-27, 1981.
15. Marcovici, M., O'Brien, C.P., McLellan, A.T., Kacian, J.: A clinical, controlled study of levo-alpha-acetylmethadol in the treatment of narcotic addiction. American Journal of Psychiatry, 138(2):234-236, 1981.

16. McLellan, A.T., Ball, J.C., Rosen, L., O'Brien, C.P. Pretreatment source of income and response to methadone maintenance: A follow-up study. American Journal of Psychiatry, 138(6):785-789, 1981.
17. LaPorte, D., McLellan, A.T., Erdlen, F., Parente, R. Treatment outcome as a function of follow-up difficulty in substance abusers. Journal of Consulting and Clinical Psychology, 49(1):112-119, 1981.
18. LaPorte, D., McLellan, A.T., O'Brien, C.P., Marshall, J. Treatment response in psychiatrically impaired drug abusers. Comprehensive Psychiatry, 22(4):411-419, 1981.
19. O'Brien, C.P., Woody, G.E., McLellan, A.T. Long-term consequences of opiate dependence. New England Journal of Medicine, 304(18): 1098-1099, 1981.
20. Stitzer, M.L., Griffiths, R.R., McLellan, A.T., Grabowski, J., Hawthorne, J.W., Diazepam use among methadone patients: Patterns and dosages. Drug and Alcohol Dependence, 8(1981): 189-199, 1981.
21. McLellan, A.T., Erdlen, F.R., Erdlen, D.L., O'Brien, C.P. Psychological severity and response to alcoholism rehabilitation. Drug and Alcohol Dependence, 8(1981): 23-35, 1981.
22. McLellan, A.T., Woody, G.E., Luborsky, L., O'Brien, C.P. Druley, K.A. Is treatment for substance abuse effective? JAMA, 247(10): 1423-1428, 1982.
23. McLellan, A.T., Luborsky, L., Woody, G.E., Druley, K.A., O'Brien, C.P. Predicting response to alcohol and drug abuse treatments: Role of psychiatric severity, Arch. Gen. Psychiat., 40(1983): 620-625, 1983.
24. McLellan, A.T., Luborsky, L., Woody, G.E., O'Brien, C.P., Druley, K.A. Increased effectiveness of substance abuse treatment: A prospective study of patient-treatment "matching". Journal of Nervous and Mental Disease, 171(10): 597-605, 1983.
25. Greenstein, R.A., Evans, B.L., McLellan, A.T., O'Brien, C.P. Predictors of favorable outcome following naltrexone treatment. Drug and Alcohol Dependence, 12(1983): 173-180, 1983.
26. Woody, G.E., Luborsky, L., McLellan, A.T., O'Brien, C.P., Beck, A.T., Blane, J., Hole, A., and Herman, I. Psychotherapy for opiate addicts: Does it help? Archives of General Psychiatry, 40 (1983):639-645, 1983.
27. O'Brien, C.P., Woody, G.E., McLellan, A.T. Modern treatment of substance abuse. Drug and Alcohol Dependence, 11: 95-97, 1983.
28. McLellan, A.T., Griffith, J., Childress, A.R., and Woody, G.E. The psychiatrically severe drug abuse patient: Methadone maintenance or therapeutic community? American Journal of Drug and Alcohol Abuse, 10(1):77-95, 1984.
29. Woody, G.E., McLellan, A.T. and Luborsky, L., O'Brien, C.P., Blaine J.D., Fox, Sonja, Herman, Ira, and Beck Aaron T. Severity of psychiatric symptoms as a predictor of

benefits from psychotherapy: The veteran's administration- Penn study. American Journal of Psychiatry, 141:10, 1172-1177, 1984.

30. Woody, G.E., Luborsky, L., McLellan, A.T., O'Brien, C.P., Beck, A T, Blaine, J, Herman, I, Hole, A, Psychotherapy for Opiate Addicts. Psychopharmacology Bulletin, 19: 766-772, 1984.
31. Woody, G.E., O'Brien, C.P., McLellan, A.T. Treatments for Opiate dependence. Psychiatry Annals, 14(4):257-263, 1984.
32. Luborsky, L., McLellan, A.T., Woody, G.E., O'Brien, C.P., Auerbach, A. Therapist success and its determinants. Archives of General Psychiatry, 42: 602-611, 1985.
33. McLellan, A.T., Luborsky, L., Cacciola, J., Griffith, J., Evans, F., Barr, H.L., and O'Brien, C.P. New data from the Addiction Severity Index: Reliability and validity in three centers. Journal of Nervous and Mental Disease., 173(7): 412 -23, 1985.
34. Childress, A.R., McLellan, A.T., O'Brien, C.P. Behavioral therapies for substance abuse. International Journal of the Addictions, 20(6&7): 947-969, 1985.
35. Woody, G.E., McLellan, A.T., Luborsky, L., O'Brien, C.P. Sociopathy and Psychotherapy Outcome. Archives of General Psychiatry, 42: 1081-1086, 1985.
36. McLellan, A. T. Childress, A. R., O'Brien, C. P., Ehrman, R. and Pashko, S. Extinguishing conditioned responses during opiate dependence treatment: Turning laboratory findings into clinical procedures. Journal of Substance Abuse Treatment, 3: 33-40, 1986.
37. Luborsky, L. Crits-Cristoph, P., McLellan, A.T., Woody, G.E., Piper, W., Lierberman, B., Imber, S., and Plikonis, P. Do therapists vary much in their success? Findings from four outcome studies. American Journal of Orthopsychiatry. 56(4): 501-512, 1986.
38. Childress AR., McLellan A.T. & O'Brien C.P. Abstinent opiate abusers exhibit conditioned craving, conditioned withdrawal and reductions in both through extinction. British Journal of. Addiction, 81(1986): 655-660, 1986.
39. Childress AR., McLellan A.T. & O'Brien C.P. Role of conditioning factors in the development of drug dependence. Psychiatric Clinics of North America., 9(3): 413-425, 1986.
40. Childress AR., McLellan A.T. & O'Brien C.P. Conditioned responses in a methadone population: A comparison of laboratory, clinic and natural settings. J. Substance Abuse Treatment, 3 173-179, 1986.
41. Milby J.B., Gurwitch R.H., Weibe D.J., Ling W., McLellan A.T. and Woody G.E. Prevalence diagnostic reliability of methadone maintenance detoxification fear. American Journal of Psychiatry, 143(6): 739 - 743, 1986.
42. Alterman A.I., McLellan A.T. A factor-analytic study of Tarter's Hyperactivity-MBD Questionnaire. Addictive Behaviors, 11, 287-294, 1986.

43. Woody, G.E., McLellan, A.T., Luborsky, L., O'Brien C.P. Twelve-month follow-up of psychotherapy for opiate dependence. American Journal of Psychiatry, 144(5): 590-596, 1987.
44. Wang, R., Mallon, J., Alterman, A.I., & McLellan, A.T. Alcohol and dilated cardiomyopathy: incidence and correlation with clinical outcome. Journal of Substance Abuse Treatment, 4: 209-213, 1988.
45. McLellan, A.T., Woody G.E., Luborsky L., Goehl, L. Is the counselor an "Active Ingredient" in substance abuse rehabilitation? Journal of Nervous and Mental Disease., 176(7): 423-430, 1988.
46. O'Brien C.P., Terenius L., Nyberg F., McLellan A.T., Eriksson I. Endogenous opioids in cerebrospinal fluid of opioid-dependent humans. Biol. Psychiatry, 24: 649-662, 1988.
47. O'Brien C.P., Childress A.R., Arndt I.O., McLellan A.T., Woody G.E., Maany I. Pharmacological and behavioral treatments for cocaine dependence: Controlled studies. Journal of Clinical Psychiatry, 49(2): 17-22, 1988.
48. Arndt I.O., McLellan A.T., O'Brien C.P. Abstinence treatments for opiate addicts: Therapeutic community or Naltrexone? Journal of Substance Abuse Treatment, 275-281, 1989.
49. O'Brien C.P., Woody G.E., McLellan A.T., Driscoll G., Childress A.R., Alterman A.I., Ehrman R., Metzger D. Reports from research centers: Substance abuse treatment research center Philadelphia VA medical center and the University of Pennsylvania. British Journal of Addiction, 83: 1261 – 1270, 1989.
50. Gerstley L., McLellan A.T., Alterman A.I., Woody G.E., Luborsky, L., and Prout, M., Ability to form an alliance with the therapist: A possible marker of prognosis for patients with antisocial personality disorder. American Journal of Psychiatry, 146(4): 508-512, 1989.
51. Gerstley L.J., Alterman A.I., McLellan A.T., Woody G.E. Antisocial personality disorder in patients with substance abuse disorders: A problematic diagnosis? American Journal of Psychiatry, 147(2): 173-178, 1990.
52. O'Brien C.P., Childress A.R., McLellan A.T., Ehrman R. Integrating systematic cue exposure with standard treatment in recovering drug dependent patients. Addictive Behaviors, 15: 355-365, 1990.
53. Wang R.Y., Alterman A.I., Searles J.S., McLellan A. T. Alcohol abuse in patients with dilated cardiomyopathy: Laboratory vs. Clinical Detection. Arch/ Intern Med. 150: 1079-1082, 1990.
54. Woody G.E., McLellan A.T., and O'Brien C.P. Research on psychopathology and addiction: treatment implications. Drug and Alcohol Dependence, 25: 121-123, 1990.
55. Alterman A.I., Hall J., Purtill J.J., Searles J., Holohan J., McLellan A.T. Heavy drinking and its correlates in young men. Addictive Behaviors. 15:95-103, 1990.

56. Woody G.E., McLellan A.T., Alterman A.I. and O'Brien C.P. Encouraging collaboration between research and clinical practice in alcohol and other drug abuse treatment. Alcohol Health and Research World, 15(3): 221 - 227, 1991.
57. Gottheil E., McLellan A.T., Druley K.A. Length of stay, patient severity and treatment outcome: Sample data from the field of alcoholism. Journal of Studies on Alcohol, 53(1): 69-75, 1992.
58. Alterman A.I., Droba M. and McLellan A. T. Response to Day Hospital Treatment by Patients with Cocaine and Alcohol Dependence. Hospital and Community Psychiatry, 43 (9): 930-932 1992.
59. Watkins K.E., Metzger D.S., Woody G.E. and McLellan A.T. High risk sexual behaviors of intravenous drug users in and out of treatment: Implications for the spread of HIV infection. American Journal Drug and Alcohol Abuse, 18 (4), 389 - 398, 1992.
60. Arndt I.O., Dorozynsky L., McLellan A.T., Woody G.E., and O'Brien C.P. Desipramine treatment of cocaine dependence in methadone maintained patients. Arch Gen. Psychiatry, 49: 888-893, 1992.
61. McKay J.R., McLellan A.T., and Alterman A.I. An evaluation of the Cleveland Criteria for inpatient treatment of substance abuse. American Journal of Psychiatry, 149(9): 1212-1218, 1992.
62. McLellan A.T., Kushner H., Metzger, D., Peters R., Smith I., Grissom, G., Pettinati H., Argeriou, The Fifth Edition of the Addiction Severity Index, Journal Substance Abuse Treatment, 9: 199-213, 1992.
63. Metzger D., Woody G.E., DePhillips D., McLellan A.T., O'Brien C.P., Platt J., Risk factors for needle sharing among methadone-treated patients. American Journal of Psychiatry, 148(5): 636-640, 1991.
64. Crits-Christoph P., Baranackie K., Kurcias, J., Beck A.T., Carroll K., Perry, K., Luborsky L., McLellan A.T., Woody, G., Thompson, L., Gallagher, D., and Zitrin, C., Meta-analysis of therapist effects in psychotherapy outcome studies. Psychotherapy Research, 1(2): 81-91, 1991.
65. Grissom G.R., McLellan A.T., Cosgrove S., DeSimone R.S., and Veitch K.W. Substance Abuse Research in an EAP Treatment Network: Barriers and Benefits. Employee Assistance Quarterly, 7(4): 59-75, 1992.
66. McLellan A.T., Alterman A.I., Woody G.E., Metzger D. A new measure of substance abuse treatment: Initial studies of the Treatment Services Review. Journal of Nervous & Mental Disease, 180(2): 101-110, 1992.
67. Gariti P., Auriacombe M., Incmikoski R., McLellan A.T., Patterson L., Dhopes V., Mezocho J., Patterson M. and O'Brien C.P. A randomized, double-blind study of Neuroelectric Therapy in opiate and cocaine detoxification. Journal of Substance Abuse, 4: 299-308, 1992.

68. Stone A.M., Greenstein R.A., Gamble G., McLellan A.T. Cocaine use by schizophrenic outpatients who receive depot neuroleptic medication. Hospital and Community Psychiatry, 44(2): 176-177, 1993.
69. McLellan A.T., Grosman D.S., Blaine J.D., Haverkos H.W. Acupuncture treatment for drug abuse: A Technical review. Journal of Substance Abuse Treatment, 10: 569 - 576, 1993.
70. Metzger D.S., Woody G.E., McLellan A.T., O'Brien C., Druley P., Navaline, H., DePhillips D., Stolley P. and Abrutyn E. Human Immunodeficiency Virus seroconversion among intravenous drug users in and out of treatment: An 18-month Prospective Follow-up. Journal of Acquired Immune Deficiency Syndrome, 6: 1049 - 1056, 1993.
71. McLellan A.T., Arndt I.O Metzger D., Woody G.E., O'Brien. The effects of psychosocial services in substance abuse treatment. JAMA, 69(15): 1953 - 1959, 1993.
72. Luborsky L., Diguer L., Luborsky E., McLellan A.T. and Woody G.E., Alexander, L. Psychological health-sickness as a predictor of outcomes in dynamic and other psychotherapies. Journal of Consulting and Clinical Psychology. 61(4): 542-548, 1993.
73. Alterman A.I., McLellan A.T. and Shiffman R.B. Do substance abuse patients with more psychopathology receive more treatment? Journal of Nervous and Mental Disease. 181(9): 576-582, 1993.
74. Bekir P., Gariti P., McLellan A.T., Childress A.R. Role reversals in families of substance misusers: A trans-generational phenomenon. International Journal of the Addictions, 28(7), 613-630, 1993.
75. McLellan A.T., Grissom G., Brill, P., Durell, J., Metzger, D., and O'Brien, C.P. Private substance abuse treatments: Are some programs more effective than others? Journal of Substance Abuse Treatment, 10: 243-254, 1993.
76. Watkins K.E., Metzger D.S., Woody G.E. and McLellan A.T. Determinants of condom use among intravenous drug users. AIDS. 7: 719-723, 1993.
77. Milby J.B., Hohmann A., Gentile M., Huggins N., Sims M.K., McLellan A.T., Woody G.E., Haas N. Methadone maintenance outcome as a function of detoxification phobia. American Journal of Psychiatry, 151(7): 1031-1037, 1994.
78. Zanis, D. A., McLellan, A. T., Randall, M. Can you trust self-reports of substance use during treatment. Drug and Alcohol Dependence, 35, 127-132, 1994.
79. Zanis, D. A., McLellan, A. T., Cnaan, R., Randall, M. Reliability and validity of the Addiction Severity Index with a homeless sample. Journal of Substance Abuse Treatment, 11(6): 541-548, 1994.
80. McKay J.R., Alterman A.I., McLellan A.T. and Snider E. Treatment goals, continuity of care, and outcomes in a day hospital substance abuse rehabilitation program. American Journal of Psychiatry, 151(2): 254 - 259, 1994.

81. Alterman A.I., O'Brien C.P., McLellan A.T., August D.S., Snider E.C., Droba M., Cornish J.C., Hall C.P., Raphaelson A. and Schrade F. Effectiveness and costs of inpatient versus day hospital cocaine rehabilitation. Journal of Nervous and Mental Disease. 182(3): 157 - 163, 1994.
82. McLellan A.T., Alterman A.I., Metzger D. S., Grissom G., Woody G.E., Luborsky L. and O'Brien C.P. Similarity of outcome predictors across opiate, cocaine and alcohol treatments: role of treatment services. Journal of Consulting and Clinical Psychology, 62(6): 1141 - 1158, 1994.
83. Zanis, D. A., Metzger, D.S., McLellan, A.T. Factors associated with employment among methadone patients. Journal of Substance Abuse Treatment, 11(5), 443-447, 1994.
84. Fureman I., McLellan A.T., Alterman A.I. Training for and maintaining interviewer consistency with the ASI. Journal of Substance Abuse Treatment, 11(3): 233 - 237, 1994.
85. McKay JR, Alterman AI, McLellan AT, Snider EC, O'Brien, CP., Effect of random versus nonrandom assignment in a comparison of inpatient and day hospital rehabilitation for male alcoholics. Journal of Consulting and Clinical Psychology, 63(1): 70-78, 1995.
86. Cacciola, J.S., Durell, J., & McLellan, A.T. Basic decisions in planning outcome studies: Careful planning will determine the "outcome" of outcome research. Behavioral Health Management, (15), 12-13, 1995.
87. Zanis, D. A., McLellan, A. T., Cacciola, J., and Vrublevski, A. DSM-III-R alcohol dependence criteria in Russian and American men. Journal of Substance Abuse, 7(2): 253-261, 1995.
88. Meyers, K., McLellan, A. T., Jaeger, J. L., & Pettinati, H. M. The development of the Comprehensive Addiction Severity Index for Adolescents (CASI-A): An interview for assessing the multiple problems of adolescents. Journal of Substance Abuse Treatment, 12(3): 181-193, 1995.
89. Meyers K., Metzger D.S., McLellan A.T. Navaline H., Sheon, A.R., Woody G. Preventive HIV vaccine efficacy trials be possible with female injection drug users? Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology, 10: 577-585, 1995.
90. Woody G.E., McLellan A.T., Luborsky L., O'Brien C.P. Psychotherapy in community methadone programs: A validation study, American Journal of Psychiatry, 152(9): 1302-1308, 1995.
91. Luborsky L., McKay J., Mercer D., Johnson S., Schmidt K., McLellan A.T. and Barber J. To use or to refuse cocaine - the deciding factors. Journal of Substance Abuse, 7: 293-310, 1995.
92. Goubert D., McKay J.R., Burke M., McLellan A.T., Randall M., Alterman A.I.: Reliability and predictive validity of the Treatment Program Progress Rating Scale. American Journal of Addictions, 5: 174-180, 1996.

93. Zanis, D. A., McLellan, A. T., & Alterman, A. I., Cnaan, R.A. Efficacy of enhanced outreach counseling to re-enroll high risk drug users 1 year after discharge from treatment. American Journal of Psychiatry, 153(8): 1095-1096, 1996.
94. O'Brien C.P. and McLellan A.T. Myths about the treatment of addiction. Lancet, 347: 237 - 240, 1996.
95. Lawental E., McLellan A.T., Grissom G., Brill P. and O'Brien, C.P. Coerced treatment for substance abuse problems detected through workplace urine surveillance: Is it effective? Journal of Substance Abuse, 8(1), 115 – 128, 1996.
96. Alterman, A., McKay, J., Mulvaney F. and, McLellan, A.T. Prediction of attrition from day hospital treatment in lower socioeconomic cocaine-dependent men. Drug and Alcohol Dependence, 40: 227 - 233, 1996.
97. McLellan A.T., Woody G.E., Metzger D., McKay J., Alterman A.I. and O'Brien C.P. Evaluating the effectiveness of addiction treatments: Reasonable expectations, appropriate comparisons. The Milbank Quarterly, 74 (1): 51 - 85, 1996.
98. Milby J.B., Sims M.K., Khuder S., Schumacher J., Huggins N., McLellan A.T., Woody G.E., Haas N. Psychiatric comorbidity: Prevalence in methadone maintenance treatment. American Journal Drug and Alcohol Abuse, 22(1): 95-107, 1996.
99. O'Brien C.P. and McLellan A.T., Addiction medicine. JAMA. 277(23): 1840 – 1841, 1997.
100. Hu T., Hunkeler E.M., Weisner C., Li E., Grayson D.K., Westphal J., and McLellan A.T. (1997), Treatment participation and outcome among problem drinkers in a managed care alcohol outpatient treatment program. Journal of Mental Health Administration. 24(1): 23-34, 1997.
101. Zanis D., McLellan A.T., Belding, A., and Moyer, G. A comparison of three methods of measuring the type and quantity of services provided during substance abuse treatment. Drug and Alcohol Dependence, 49: 25 – 32, 1997.
102. Kraft M.K., Rothbard A.B., Hadley T.R., McLellan A.T. and Asch D.A. Are supplementary services provided during methadone maintenance really cost effective? American Journal of Psychiatry, 154(9): 1214-1219, 1997.
103. French M.T., Dunlap L.J., Zarkin G.A., McGeary K.A. and McLellan A.T. A structured instrument for estimating the economic cost of drug abuse treatment: The Drug Abuse Treatment Cost Analysis Program (DATCAP). Journal of Substance Abuse Treatment, 14(5): 445-455, 1997.
104. McLellan A.T., Grissom G., Zanis D., Randall, M., Brill, P., and O'Brien, C. Problem - Service "Matching" In Addiction Treatment: A prospective study in 4 programs. Archives of General Psychiatry, 54: 730 – 735, 1997.
105. Lundy A., Gottheil E., McLellan A.T., Weinstein S.P., Sterling R., and Serota, R. Underreporting of cocaine use at post-treatment follow-up and the measurement of

- treatment effectiveness. Journal of Nervous and Mental Disease. 185(7): 459 – 462, 1997.
106. Zanis, D. A., McLellan, A. T., Corse, S. Is the Addiction Severity Index a reliable and valid assessment instrument among clients with severe and persistent mental illness and substance abuse disorders? Community Mental Health Journal, 33(3): 213-227, 1997.
 107. Gastfriend D. and McLellan A.T. Treatment Matching: Theoretical basis and practical implications. Alcohol and Other Substance Abuse, 81(4): 945-966, 1997.
 108. McLellan A.T., Hagan T.A., Meyers K., Randall M. and Durell J. “ Intensive” outpatient substance abuse treatment: Comparisons with “ traditional” outpatient treatment. Journal of Addictive Diseases, 16(2): 57 - 84. 1997.
 109. McKay, J., Cacciola J., Alterman, A., McLellan, A.T., and Wirtz P. An initial evaluation of the psychosocial dimensions of the American Society on Addiction Medicine Criteria for inpatient versus intensive outpatient substance abuse rehabilitation. Journal of Studies on Alcohol, 58: 239-252, 1997.
 110. Fureman, I. Meyers K, McLellan A.T., Metzger D.S., Woody G. Evaluation of a video supplement to informed consent: Injection drug users and preventive HIV vaccine efficacy trials. AIDS Education and Prevention, 9(4): 330 – 341, 1997.
 111. Luborsky L., McLellan A.T., Diguier L., Woody G.E. and Seligman D. The psychotherapist matters: Comparison of outcomes across twenty-two therapists and seven patient samples. Clinical Psychology: Science and Practice, 4: 53-65, 1997.
 112. Cornish J., Metzger D., Woody G., Wilson D., McLellan A.T., Vandergrift B., O'Brien C.P. Naltrexone pharmacotherapy for opioid dependent federal probationers. Journal of Substance Abuse Treatment, 14(6): 529 – 534, 1997.
 113. McLellan, A.T., Hagan T.A., Meyers K., Levine M., Gould F., Bencivengo M., Durell J. Jaffe J., Supplemental Social services improve outcomes in public addiction treatment. Addiction, 93(10), 1489 – 1499, 1998.
 114. Belding, M. A., McLellan, A. T., Zanis, D. A., Incmikoski, R., Characterizing "non-Responsive" Methadone Patients. Journal of Substance Abuse Treatment, 15(6): 485-492, 1998.
 115. McKay, J.R., McLellan, A.T., Durell, J., Ruetsch, C., & Alterman, A.I., Characteristics of recipients of Supplemental Security Income (SSI) benefits for drug addicts and alcoholics. Journal of Nervous and Mental Disease, 186 (5) 290 – 298, 1998.
 116. Cacciola J.S., Alterman A., Rutherford M., McKay J., McLellan T. The early course of change in methadone maintenance, Addiction, 93(1): 41-49, 1998.
 117. McKay J.R., McLellan A.T., Alterman A.I, Cacciola J.S., Rutherford M.R., O'Brien C.P., Predictors of participation in aftercare sessions and self-help groups following completion of intensive outpatient treatment for substance abuse, Journal of Studies on Alcohol, 59: 152-162, 1998.

118. McKay, J.R., Alterman, A.I., McLellan, A.T., Boardman, C., Mulvaney F. and O'Brien, C.P. Random versus non-random assignment in the evaluation of treatment for cocaine abusers. Journal of Consulting Clinical Psychology, 66(4): 697-701.
119. McLellan A.T. and Hunkeler, E., Patient satisfaction and outcomes in alcohol and drug abuse treatment. Psychiatric Services, 49(5): 573-575, 1998.
120. Butler, S.F., Newman, F.L., Cacciola J.S., Frank A., Budman S., and McLellan A.T. (1998) Predicting Addiction Severity Index (ASI) Interviewer Severity Ratings for a computer-administered ASI. Psychological Assessment, 10 (4) 399-407, 1998.
121. McKay, J.R., Alterman, A.I., Rutherford, M.J., Cacciola, J.S., & McLellan, A.T., The relationship of alcohol use to cocaine relapse in cocaine dependent patients in an aftercare study. Journal of Studies on Alcohol, 60: 176-180, 1999.
122. Carise D., McLellan A.T., Gifford L. and Kleber H., Developing a national addiction treatment information system: An introduction to the Drug Evaluation Network System. Journal of Substance Abuse Treatment, 17(1-2): 67-77, 1999.
123. Watkins, K.A., Wells K.B. and McLellan, A.T., Termination of social security benefits among Los Angeles recipients disabled by substance abuse. Psychiatric Services, 50(7): 914 – 918, 1999.
124. Meyers, K., Hagan, T. A., Zanis, D., Webb, A., Frantz, J., Ring-Kurtz, S., Rutherford, M., & McLellan, A. T., Critical issues in adolescent substance abuse assessment. Drug and Alcohol Dependence, 55: 235-246, 1999.
125. McLellan, A.T., Levine M., Hagan T.A., Meyers K., Randall, M., Gould F., Bencivengo M., Durell J., Does Clinical Case Management Improve Outpatient addiction treatment? Drug and Alcohol Dependence 55: 91 – 103, 1999.
126. French, M.T., H.J. Salomé, A. Krupski, J.R. McKay, D.M. Donovan, A.T. McLellan, and J. Durell., Benefit-Cost Analysis of Residential and Outpatient Addiction Treatment in the State of Washington. Evaluation Review, 24(6): 609-634, 2000.
127. French M.T., Roebuck MC, McLellan A.T., Sindelar J.L., Can the Treatment Services Review be used to estimate the costs of addiction treatment and ancillary services? Journal of Substance Abuse, 12: 341-361, 2000.
128. Weinreib, R.W., VanHorn D.V., Lucey M.R. and McLellan A.T., Interpreting the significance of drinking by alcohol dependent liver transplant patients: Fostering candor is the key to recovery. Liver Transplantation, 6(6): 769 – 776, 2000.
129. Alterman A.I., Shen Q., Merrill J., McLellan A.T., Durell J., McKay J., Treatment services received by Supplemental Social Security Income drug and alcoholic clients. Journal of Substance Abuse Treatment. 18: 209-215, 2000.
130. Weisner C., Connell C., Hunkeler E., Rice D., McLellan A.T., Hu T. and Moore C. Drinking patterns and problems of the "stably insured": A study of the membership of a health maintenance organization. Journal of Studies on Alcohol, 61: 121-129, 2000.

131. McLellan A.T., Weisner C.M. and Smith W. (Editors), Women and Alcohol Problems: A Critical Analysis of the Literature and Unanswered Questions. Alcoholism: Clinical and Experimental Research, 24(8): 1320-1321, 2000.
132. Alterman A.I., Randall M. and McLellan A.T., Comparison of outcomes by gender and for fee-for service versus managed care: A study on none community programs. Journal of Substance Abuse, 19: 127-134, 2000.
133. Carise D., McLellan A.T., Gifford L. and Kleber H. Development of a Treatment Program Descriptor: The Addiction Treatment Inventory. Substance Use and Misuse, 35(12-14): 1797-1818, 2000.
134. McLellan A.T., Weisner C. and Hunkeler E.M., Addiction Severity Index data from General Membership and Treated Samples of HMO Members: One case of Norming the ASI. Journal of Substance Abuse Treatment, 19: 103-109, 2000.
135. Shen Q., McLellan A.T., and Merrill J. Client's perceived need for treatment and its impact on outcome. Journal of Substance Abuse, 21(3): 179-192, 2000.
136. McLellan A.T., O'Brien C.P., Lewis D. L. and Kleber H.D. Drug dependence, a chronic medical illness: Implications for treatment, insurance and outcomes evaluation. JAMA 284(13): 1689-1695, 2000.
137. Dennis M.I., Perl H.I., Huebner R.B., McLellan A.T., Twenty-five strategies for improving the design, implementation and analysis of health services research related to alcohol and other drug abuse treatment. Addiction, 95(Supplement 3): S281-308, 2000.
138. Gould F., Levine M. and McLellan A.T. Treating the substance abusing patient in the public sector: "Medical Necessity vs. "Social Necessity and Social Responsibility" in the Philadelphia Target Cities Demonstration Project. Journal of Substance Abuse Treatment, 18: 75-77, 2000.
139. Carise D., McLellan A.T., Gifford L., Development of a Treatment Program Descriptor: The Addiction Treatment Inventory. Journal of Substance Abuse, 35(12-14): 1797-1819, 2000.
140. McLellan A.T., Moving toward a third generation of contingency management studies in the drug abuse treatment field: Comment on Silverman, et al. Experimental and Clinical Psychopharmacology, 9(1): 29-32, 2001.
141. Marlowe D.B., Kirby K.C., Merikle E.P., Festinger D.S., and McLellan A.T, Multidimensional assessment of perceived treatment-entry pressures among substance abusers. Psychology of Addictive Behaviors, 15(2) 97 – 108, 2001.
142. McKay, J.R., Donovan, D.M., McLellan, A.T. Krupski, A. Hantsen, M. and Stark, K., Evaluation of Full vs. Partial Continuum of Care in the Treatment of Publicly-funded Substance Abusers in Washington State. American Journal of Drug and Alcohol Dependence, 28(2): 307-328, 2002.

143. McLellan A.T., A randomized controlled trial of brief cognitive-behavioral interventions for cannabis use disorder. Journal of Substance Abuse Treatment, 21: 55-64, 2001.
144. Weinreib, R.W., VanHorn D.V., Lucey M.R. McLellan A.T., Alterman A.I., Calarco J., and O'Brien C.P., Alcoholism treatment after liver transplantation: Lessons learned from a clinical trial that failed. Psychosomatics, 42(2): 110-116, 2001.
145. Carise, D., McLellan, A.T., Cacciola, J.S., Love, M., Cook, T., Bovasso, G., & Lam, V., Suggested specifications for a standardized Addiction Severity Index database. Journal of Substance Abuse Treatment, 20: 239-244, 2001.
146. Weinreib, R.W., VanHorn D.V., McLellan A.T. Volpicelli, J R., Calarco, J.S., Lucey M.R., Drinking behavior and motivation for treatment among alcohol dependent liver transplant candidates. Journal of Addictive Diseases, 20(2): 105-119, 2001.
147. Carise, D, Cornely, W., & Gürel, O., successful researcher-practitioner collaboration in substance abuse treatment. Journal of Substance Abuse Treatment, 23: 157-162, 2002.
148. Festinger D.S., Marlowe D.B., Lee P.A., Kirby K.C., Bovasso G. and McLellan A.T., Status hearings in drug court: When more is less and less is more. Drug and Alcohol Dependence, 68: 151 – 157, 2002.
149. Garnick, D., Lee M., Chalk M., Gastfriend D., Horgan C., McCorry F., McLellan A.T., Establishing the Feasibility of Performance Measures for Alcohol and Other Drugs. Journal of Substance Abuse Treatment, 23: 375-385, 2002.
150. French, M.T., K.E. McCollister, J. Cacciola, A.T. McLellan, and J. Durell., Benefit-Cost Analysis of Addiction Treatment in Arkansas: Specialty and Standard Residential Programs for Pregnant and Parenting Women. Journal of Substance Abuse, 23: 31-51, 2002.
151. McLellan A.T., Technology transfer and the treatment of addiction. What can research offer practice? Substance Abuse, 22: 169-170, 2002.
152. Harkely A., Randall M. and McLellan A.T., Analysis of the Black Racial Identity Attitude Scale in the Substance Abusing Population. Journal of the National Medical Association, 94(6): 459-471, 2002.
153. McLellan A.T., Have we evaluated addiction treatment correctly? Implications from a chronic care perspective. Addiction, 97: 249-252, 2002.
154. Hilton M., Fleming M., Glick H., Gutman M., Lu Y., McKay J., McLellan A.T., Maning W., Meadows J., Mertens J., Moore C., Mullahy C., Mundt M., Parthasarathy S., Polsky D., Ray G.T., Sterling S. and Weisner C., Services Integration and Cost Effectiveness. Alcoholism: Clinical and Experimental Research, 27(2): 271-280, 2003.
155. McLellan A.T. (2004), What's the harm in discussing harm reduction: An introduction to a three-paper series. Journal of Substance Abuse Treatment, 25: 239-240, 2003.

156. Marlowe D.B., Elwork A., Festinger D. and McLellan A.T., Drug Policy by Popular Referendum: This too shall pass. Journal of Substance Abuse Treatment. 25: 213-221, 2003.
157. Gutman M, Ketterlinus R, and McLellan A T, Characteristics of Substance-Abusing Women on Welfare: Findings from the Evaluation of the "CASAWORKS for Families" Pilot Demonstration. Evaluation Review, 27(6): 597-628, 2003.
158. McLellan A T, Lynch, K., Gutman M, McKay JR, Ketterlinus R, Morgenstern J and Woolis D., One-Year Outcomes from the "CASAWORKS for Families" Intervention for Substance Abusing, Women on Welfare. Evaluation Review, 27(6): 656 – 680, 2003.
159. McKay JR, Gutman M, McLellan A T, Ketterlinus R, and Lynch, K. Treatment Services Received in the "CASAWORKS for Families" Program. Evaluation Review, 27 (6): 629 – 655, 2003.
160. Gutman M, McKay JR, Ketterlinus R, and McLellan A T, Potential Barriers to Work for Substance-Abusing Women on Welfare: Findings from the Evaluation of the "CASAWORKS for Families" Pilot Demonstration. Evaluation Review, 27 (6): 681 – 706, 2003.
161. McLellan A.T., Kleber H.D. and Carise D. The national addiction treatment infrastructure: Can it support the public's demand for quality care? J. Substance Abuse Treatment, 25: 117-121, 2003.
162. Roebuck M.C., French M. and McLellan A.T., DATStats: Results from 85 Studies using the Drug Abuse Treatment Cost Analysis Program (DATCAP). Journal of Substance Abuse Treatment, 25: 51-57, 2003.
163. McLellan A.T., Crime and punishment and treatment: Latest findings in the treatment of drug-related offenders. J. Substance Abuse Treatment, 25: 187-188, 2003.
164. Salome, H.J., French, M., T.Miller, M. and A.T. McLellan., Estimating the client costs of addiction treatment: First findings from the client drug abuse treatment cost analysis program. Drug and Alcohol Dependence. 71: 195-206, 2003.
165. Fiellin D., Kleber, H.D., Trumble-Hejduk, J., McLellan, A.T., and Kosten, T.R. Consensus Statement on Office-based Treatment of Opioid Dependence using Buprenorphine. Journal of Substance Abuse Treatment, 27: 153-159, 2004.
166. French, M.T., H.J. Salome, J.L. Sindelar, and A.T. McLellan., Benefit-Cost Analysis of Addiction Treatment: Methodological Guidelines and Empirical Application Using the DATCAP and ASI. Health Services Research. 37(2): 433-455, 2002.
167. McLellan A. T. and Meyers K., Contemporary Addiction Treatment: A Review of Systems Problems for Adults and Adolescents. Biological Psychiatry, 56: 764-770, 2004.
168. Sindelar, J.L., Jofre-Bonet M., French M.T., McLellan A.T., Cost Effectiveness analysis of treatment: Paradoxes of multiple outcomes. Drug and Alcohol Dependence, 73: 41-50, 2004.

169. Humphreys, K., Wing, S., McCarty, B., Chappel, J., Gallant, L., Haberle, B., Horvath, T., Kaskutas, L., Kirk, T., Kivlahan, D., Laudet, A., McCrady, B., McLellan, T., Morgenstern, J., Townsend, M., & Weiss, R., Self-help organizations for alcohol and drug problems: Toward evidence-based practice and policy. Journal of Substance Abuse Treatment, 26: 151–158, 2004.
170. Carise D, Festinger D.S., McLellan A. T. and Kleber H.D., Identifying the United States Substance Abuse Treatment Programs: A Partial Test in One Mid-Sized City. Journal of Substance Abuse, 25(2): 21-28, 2004.
171. French, M.T., K.E. McCollister, and A.T. McLellan, Cost estimation when time and resources are limited: The brief DATCAP. Journal of Substance Abuse Treatment, 27: 187-193, 2004.
172. McLellan A.T., McKay J.R., Forman R., Cacciola J., Kemp J., Reconsidering the Evaluation of Addiction Treatment: From Retrospective Follow-Up to Concurrent Recovery Monitoring. Addiction, 100: 447 – 458, 2005.
173. Carise D., Gurel O., McLellan A.T., Dugosh K. and Kendig C., Getting patients the services they need using a computer-assisted system for patient assessment and referral – CASPAR. Drug and Alc. Dependence, 80: 177 – 190, 2005.
174. Henningfield J. E. and McLellan A. T., Medications work for severely addicted smokers: Implications for addiction therapists and primary care physicians. Journal of Substance Abuse Treatment. 28: 1-2, 2005.
175. McLellan A. T., Weinstein R.L., Shen Q., Kendig C. and Levine M., Improving continuity of care in a public addiction treatment system with clinical case management. American Journal of Addictions, 14: 426-440, 2005.
176. Kimberly J. R. & McLellan, A.T., The business of addiction treatment: A research agenda. Journal of Substance Abuse Treatment, 31: 213-219, 2006.
177. Forman, R., Woody, G., McLellan, A.T. and Lynch, K., The availability of Web sites offering to sell opioid medications without prescriptions. American Journal of Psychiatry, 163:1233-1238, 2006.
178. McLellan A.T., Cacciola J., Alterman A.I., Rikoon S. H., Carise D., The ASI at 25: Origins, contributions, and transitions. American Journal on Addictions, 15: 113-124, 2006.
179. Cacciola J., Alterman A.I., and McLellan A.T., Lin, Y.T., Lynch, K. G., Initial evidence for the reliability and validity of a “Lite” version of the ASI. Drug and Alcohol Dependence. 87: 297-302, 2007.
180. McLellan A.T., Reducing heavy drinking: public health policy and a treatment goal? Journal of Substance Abuse Treatment, 33: 81-83, 2007.
181. McLellan A.T., What is Recovery? A working definition from the Betty Ford Institute. Journal of Substance Abuse Treatment, 33: 221-228, 2007.

182. McGovern M. & McLellan A.T., The status of addiction treatment research for co-occurring substance use and psychiatric disorders. Journal of Substance Abuse Treatment, 34: 1-2, 2008.
183. McLellan A.T., Kemp J., Carise D., Brooks D., Improving Public Addiction Treatment Through Performance Contracting: The Delaware Experiment, Health Policy, 87: 296-308, 2008.
184. McLellan A. T. and Turner B.J., Prescription Opioids, Overdose Deaths, and Physician Responsibility. JAMA 300(22): 2672-2673, 2008.
185. Carise D., Love M., Zur J., McLellan, A.T., Kemp J., Results of a statewide evaluation of “paperwork burden” in addiction treatment. Journal of Substance Abuse Treatment, 2009.
186. DuPont R.L., McLellan, A.T., White W., Merlo, L J., Gold M.S., Setting the standard for recovery: Physicians’ health programs. Journal of Substance Abuse Treatment, 36: 159-171, 2009.
187. Coffey R., Levit K, Kassed C., McLellan A.T., Chalk M, Brady T, Vandivort-Warren R., Evidence for substance abuse services and policy research: A Systematic Review of National Databases. Evaluation Review, 33(2): 137, 2009.

RESEARCH PUBLICATIONS, PEER REVIEWED: REQUESTED BUT ABLE TO OBTAIN ABSTRACTS ONLY

Note: the abstracts are attached at B1- A

Research Publications, Peer Reviewed: Requested but Only Abstracts Available:

1. McLellan, A.T., Druley, K.A.: Non-random relation between drugs of abuse and psychiatric diagnosis in a male psychiatric population. J. Psychiat. Res., 13:179-184, 1977.
2. Hayashida M., Alterman A.I., McLellan A.T., O'Brien C.P., Purtill J., Volpicelli J. Comparative effectiveness and costs of inpatient and outpatient medical alcohol detoxification, New Eng. J. Med., 320: 358 - 365, 1989.
3. McKay, J.R., Alterman, A.I., & McLellan, A.T. treatment goals, continuity of care, and outcome in a day hospital substance abuse rehabilitation program Am. J. Psychiat. 15: 254-259, 1994.
4. Childress A.R., Ehrman R., MacRae J.R., McLellan A.T., O'Brien C.P. Can induced moods trigger drug-related responses in opiate abuse patients? J. Subst. Abuse Trt. 11; 17 – 23,1994.
5. Alterman A.I. and McLellan A.T. Inpatient and day hospital treatment services for cocaine and alcohol dependence. Journal of Substance Abuse Treatment 10: 269-275, 1993.

6. McKay, J.R., Alterman, A.I., McLellan, A.T., Snider, E.C., and O'Brien, The Effect of Random versus Non-Random Assignment in a Comparison of Inpatient and Day Hospital Rehabilitation for Male Alcoholics. J. Clin Consult Psychol. 63; 70 - 78, 1995.
7. Zanis D. McLellan A.T., and Corse S. Is the Addiction Severity Index a Reliable and Valid Assessment Instrument Among Clients with severe and persistent mental illness? Comm. Mental Health J. 33; 213-227, 2004.
8. Arndt I.O., McLellan A.T., Dorozynsky L., Woody G.E., and O'Brien C.P. Desipramine treatment of cocaine dependence: Role of Antisocial personality disorder. J., Nerv. Ment Dis., 1994.
9. Bickel W. and McLellan A.T. Can management by Outcome Invigorate Substance Abuse Treatment?. Am. J. on Add., 5; 281 – 291, 1996.
10. Belding, M. A., Iguchi M., Morral A.R., McLellan, A. T. Assessing the helping alliance and its impact in the treatment of opiate dependence. Drug and Alcohol Dependence. 48(1): 51 – 59, 1997.
11. McKay JR, Alterman AI, Rutherford MJ, Cacciola JS, McLellan AI: The Relationship of Alcohol Use to Treatment Outcomes of Cocaine Dependent Patients. Journal of Studies on Alcohol, 60, 176-180, 1999.
12. Watkins, K.A., Wells K.B. and McLellan, A.T. Termination of social security benefits among Los Angeles recipients disabled by drug abuse. Psychiatric Services. 50(7): 914 – 918, 1999.
13. Meyers, K., Hagan, T. A., Zanis, D., Webb, A., Frantz, J., Ring-Kurtz, S., Rutherford, M., & McLellan, A. T. (1999). Critical issues in adolescent substance abuse assessment. Drug and Alcohol Dependence., 55; 235 – 246.
14. Weisner C., Connell C., Hunkeler E.N., Rice D.P., McLellan A.T., Fireman MA., Hu T., & Westphal J. (2000) Drinking patterns and problems of the stably insured. J. Stud Alc., 61; 121-129
15. Alterman A., McDermott P., Cook T., Cacciola J., McLellan A.T. (2000) Generalizability of the clinical dimensions of the Addiction Severity Index to nonopiate dependent patients. Psychology of Addictive Behaviors. 14: 287 – 294.
16. Carroll K.M., Nich C., McLellan A.T., McKay J.R., and Rounsaville B.J. (2001) Research vs. real world patients. Representativeness of patients participating in clinical trials of treatments for cocaine dependence. Drug and Alc. Dep 54; 171-177.
17. McLellan A. T. Is Addiction an Illness? Can it be Treated? (2002) Substance Abuse 23 (3S) 67 – 94. **(MS Word copy provided)**
18. Marlowe D.B., Festinger D.S., Lee P.A., Schepise M.M., Hazzard J.E.R., Merrill J.C., Mulvaney F.D. and McLellan A.T. (2002) Are Judicial Status Hearings a “key Component” of Drug Courts? During Treatment Data from a Randomized Trial. Criminal Justice and Behavior. 20(3), 239 – 244

19. McKay, J.R., Donovan, D.M., McLellan, A.T., Krupski, A., Hansten, M., Stark, K.D., Geary, K., & Cecere, J. (2004). Evaluation of full vs. partial continuum of care in the treatment of publicly-funded substance abusers in Washington State. The American Journal of Drug and Alcohol Dependence. 102: 71-77.
20. Gurel O., Carise D., Kendig C., McLellan A.T. (2005) Developing CASPAR: A computer assisted system for patient assessment and referral. J. Substance Abuse Treatment. 28: 281 - 289.

RESEARCH PUBLICATIONS, PEER REVIEWED: REQUESTED BUT UNABLE TO OBTAIN ABSTRACTS OR COPIES

1. Luborsky, L., McLellan, A.T., Woody, G.E., O'Brien, C.P., Rosenzweig, J. Are different forms of psychotherapy recognizably different? Journal of Clinical and Consulting Psychology, 50:49-62, 1981.
2. Luborsky, L., McLellan, A.T. A sound mind in a sound body - To what extent do they go together before and after psychotherapy? Psychiatry in Medicine, 10(2):408-412, 1981.
3. Hill, J.C., and McLellan, A.T. Verbal attention-seeking responses used by drug-dependent veterans. Small Group Behavior, 8:224-231, 1983.
4. Woody, G.E., Luborsky, L., McLellan, A.T., O'Brien, C.P. Psychotherapy for Opiate Addicts. Psychopharmacology Bull, 19:766-772, 1984.
5. McLellan, A.T., Luborsky, L., Griffith, J., Evans, F., Barr, H. Prediction and measurement of outcome in Substance Abuse treatment using the Addiction Severity Index. American Journal of Drug and Alcohol Abuse, 1984.
6. Woody G.E., McLellan A.T., Luborsky L., O'Brien C.P. Psychotherapy for opiate addiction Psychiatric Times, 24; 649-662, 1989.
7. Burke, W.M., Ravi, N., Maany, I., McLellan, A.T. A tailored approach to urine testing during treatment of cocaine dependence, J. Clinical Psychiatry, 1990.
8. Abellanas L., Randall M. and McLellan A. T. "Stage of change" by drug problem in Concurrent opioid, cocaine and cigarette users. J. Psychoactive Drugs 25 (4); 307 - 312, 1993.
9. Metzger, D.S., Navaline, H.S., Woody, G.E., McLellan, A.T. (2000) Risk Assessment Battery: Validity and reliability of a brief questionnaire for the measurement of HIV risk behaviors. J.AIDS
10. Weinreib, R.W., VanHorn D.V., McLellan A.T. and Lucey M.R. (2000) Interpreting the significance of drinking by alcohol-dependent liver transplant patients: Fostering candor is the key to recovery. Liver Transplant. 6(6), 769 – 776.

11. McLellan A.T. (2001) Properly acknowledging the past and the future: Editorial responsibilities for the Journal of Substance Abuse Treatment. Journal of Substance Abuse Treatment 21(1): 1 - 2.
12. McLellan A.T., Kleber H.D. , Johnson P. and Vaughn R. (2004) Addiction Severity Index Data from Admissions to a Nationally Representative Sample of Addiction Treatment Programs. J. Substance Abuse. 23: 22 - 27.
13. Simeone R., McLellan A.T. and Carise D. (2005) The Reliability and Validity of Retrospective Self-Reported Drug Use. Journal of Medical Statistics. 63: 212 - 217.
14. Festinger D.S., Marlowe D.B., Lee P.A., Kirby K.C., Bovasso G. and McLellan A.T. (2006) Client program matching effects in Drug Courts. J. Substance Abuse Treatment. 29: 78 - 90.
15. McLellan A.T. (2007) Implicit Demand Characteristics in Research Funding Sources: It's Not Just Some Sources. Addiction 38: 34 - 36.
16. White W. and McLellan A.T. (In Press) Addiction as a Chronic Disorder: Counselor 2009
17. Carise D., Brooks A., McLellan A. T., Forman R. and Hoover V. (In press) Implementing Evidence Based Practices in Community Treatment Programs: Initial feasibility of a counselor toolkit on decisional balance. Drug and Alcohol Dependence.

EDITORIALS, REVIEWS, CHAPTERS, INCLUDING PARTICIPATION IN COMMITTEE REPORTS (PRINT OR OTHER MEDIA):

Note: Copies of these items are contained at TAB B-2

1. Erdlen, F., Sobczynski, E., Broocker, B., McLellan, A.T. (1978). *Effective inpatient treatment of older alcoholics*. In Gottheil et al. (eds.) *Addiction Research and Treatment: Converging Trends*, Pergamon Press, New York, 113 - 123.
2. Woody, G.E., O'Brien, C.P., McLellan, A.T. (1979). *Depression in narcotic addicts: Possible causes and treatment*. In *Psychiatric Aspects of Drug Dependence*, Pickins, R. and Heston, L. (eds.), New York, Grune & Stratton, 105 - 124.
3. Alterman, A., Erdlen, F., McLellan, A.T. (1980). *Problem drinking in a psychiatric hospital: Alcoholic schizophrenics*. In *Substance Abuse and Psychiatric Illness*, edited by E. Gottheil, A.T. McLellan, K.A. Druley, New York: Pergamon-Maxwell, 27-37.
4. LaPorte, D., McLellan, A.T., MacGahan, J. (1980). *Evaluation of combined treatment for alcohol and drug abusers: Importance of patient compatibility*. In Madden, J.S. et al. (Eds.), *Aspects of Alcohol and Drug Dependence*, Kent, England, Pittman Medical, 290 – 304.

5. McLellan, A.T., O'Brien, C.P., Woody, G.E. (1980) *Development of Psychiatric Disorders in Drug Abusers: Relation Between Primary Drug and Type of Disorder*. NIDA Research Monograph Series, #27, USGPO, 149-155.
6. McLellan, A.T., Luborsky, L., O'Brien, C.P., Woody, G.E. (1980) *An Improved Evaluation Instrument for Substance Abuse Patients: The Addiction Severity Index*. NIDA Research Monograph Series, #37, USGPO, 142-148.
7. McLellan, A.T., O'Brien, C.P., Luborsky, L., Woody, G.E. (1981) *Certain types of substance abuse patients do better in certain kinds of treatments: Evidence for patient-program matching*. Problems of Drug Dependence, NIDA Research Monograph Series, # 34, USGPO, 123-131.
8. Woody, G.E., McLellan, A.T., O'Brien, C.P., Luborsky, L. (1981) *Personality factors in methadone self-administration by heroin addicts*. NIDA Research Monograph Series, #37, USGPO, 63-74.
9. McLellan, A.T., Luborsky, L., Woody, G.E., O'Brien, C.P. (1981). *The generality of benefits from alcohol and drug abuse treatments*. Problems of Drug Dependence 1980, NIDA Research Monograph No. 34, USGPO, 373-379.
10. McLellan, A.T., Ball, J.C., O'Brien, C.P. (1981) *Type of pre-treatment income and response to treatment in methadone maintenance*. Problems of Drug Dependence 1980, NIDA Research Monograph No. 34, USGPO, 116-122.
11. Ball, J.C., McLellan, A.T., Rosen, L. (1981). *Methadone treatment outcome for employed, dependent and criminal patients*. In E. Gottheil et al. (eds.) *Matching Patient Needs and Treatment Methods in Alcohol and Drug Abuse*, Chicago: Charles Thomas Pub., 75 - 91.
12. McLellan, A.T., Woody, G.E., O'Brien, C.P. (1981). *Drug abuse and psychiatric disorders: Examinations of some specific relationships*. In G. Nahus and H. Brill (eds.) *Drug Abuse in the Modern World*, New York, Pergamon-Maxwell, 27 - 46.
13. McLellan, A.T., Woody, G.E., Luborsky, L., O'Brien, C.P., and Druley, K.A. (1983). *Increased effectiveness of drug abuse treatment from patient-program matching*. Problems of Drug Dependence 1982, NIDA Research Monograph, #43, 335 – 341.
14. McLellan, A.T., Woody, G.E., Evans, B.D., O'Brien, C.P. (1982) *Treatment of mixed abusers in methadone maintenance: Role of psychiatric factors*, Proceedings of the N.Y.A.S., 65-78.
15. Woody G., Persky H., McLellan T.A., O'Brien C.P., Arndt I., (1982). *Psychoendocrine correlates of hostility and anxiety in addicts*. In E. Gottheil et al (eds) *Alcohol, Drug Abuse, and Aggression*, Chicago: Charles Thomas Publisher, 224-227.
16. McLellan, T.A., O'Brien C.P., Woody G., Luborsky L. Druley K. (1982). *Is drug abuse treatment effective?* Problems of Drug Dependence, NIDA Research Monograph 41, USGPO, 223-2229.

17. Greenstein, R., Evans, B., McLellan, A.T., and O'Brien, C.P. (1983) *Predictors of favorable outcome following naltrexone treatment*. Problems of Drug Dependence 1982, NIDA Research Monograph, #43, 295-301.
18. Woody, G.E., McLellan, A.T., O'Brien, C.P. (1984) *Treatment of behavioral and psychiatric problems associated with opiate dependence*. NIDA Research Monograph Series, #46, USGPO, 23-35.
19. Childress, A.R., McLellan, A.T., and O'Brien, C.P. (1984) Assessment and extinction of conditioned withdrawal-like responses in an integrated treatment for opiate dependence. NIDA Research Monograph Series, #55, USGPO, 202-210.
20. Arndt, I., McLellan, A.T., O'Brien, C.P. (1984). *Abstinence oriented treatments for opiate addicts: Therapeutic community or naltrexone*. Problems of Drug Dependence 1983, NIDA Research Monograph, USGPO, 275-287.
21. Childress, A.R., McLellan, A.T., O'Brien, C.P. (1984). *Measurement and extinction of conditioned withdrawal-like responses in opiate-dependent patients*. Problems of Drug Dependence 1983, NIDA Research Monograph, USGPO, 212-219.
22. McLellan, A.T., Childress, A.R., and Woody, G.E. (1984). *Drug abuse and psychiatric disorders: Role of drug choice*. In Alterman, A.I. (Ed.) Psychiatric Illness and Substance Abuse. New York: Plenum Press, 137-172.
23. Woody, G.E., O'Brien, C.P., McLellan, A.T., Luborsky, L. (1985). *Psychotherapy as an adjunct to methadone treatment*. In R.E. Meyer (Ed.) Psychiatric Aspects of Opiate Dependence, New York, Guilford Press, 169-195.
24. Childress, A.R., McLellan, A.T. and O'Brien, C.P. (1985) *Nature and incidence of conditioned responses in a methadone-maintenance population: A comparison of laboratory, clinic, and naturalistic settings*. NIDA Research Monograph Series, #67, USGPO, 366-372.
25. Childress, A.R., McLellan, A.T., Natale, M. & O'Brien, C. (1986) *Mood states can elicit conditioned withdrawal and craving in opiate abuse patients*. NIDA Research Monograph Series, #76, USGPO, 137-144.
26. Childress, A.R., McLellan, A.T., Ehrman, R., and O'Brien, C.P. (1987), *Extinction of conditioned responses in abstinent cocaine or opioid users*. Problems of Drug Dependence 1986, NIDA Research Monograph, USGPO, 189-195.
27. Woody G.E., McLellan A.T., O'Brien C.P., Persky H., Arndt I.O. (1987) *Hormone secretion in methadone dependent and abstinent patients*. NIDA Research Monograph Series, #81 USGPO, 216-223.
28. O'Brien C.P., Childress A.R., McLellan A.T., Ehrman R.E., Ternes J. (1988). *Progress in understanding the conditioned aspects of drug dependence*. In L. Harris Ed. Problems of Drug Dependence 1987, NIDA Research Monograph, USGPO, 395-404.

29. Babor T., Cooney R., Hubbard R., Jaffe J., Kosten T., Lavermar R., McLellan A.T., Rankin H., Rounsaville B., Skinner H. (1988). *The syndrome concept of alcohol and drug dependence: Results of the secondary analysis project*. In L. Harris Ed. Problems of Drug Dependence 1987, NIDA Research Monograph, USGPO, 33-39.
30. Childress A.R., Ehrman R., McLellan A.T., O'Brien C.P. (1988). *Conditioned craving and arousal in cocaine addiction: A preliminary report*. In L. Harris Ed. Problems of Drug Dependence 1987, NIDA Research Monograph, USGPO, 74-80.
31. Gottheil E., McLellan A.T., Druley K.A. (1988). *What is appropriate treatment duration and for whom?* Alcohol Health & Research, 12(3), 188-192.
32. O'Brien C.P., Childress A.R., McLellan A.T., Ehrman R., Ternes J. (1988). *Types of conditioning found in drug-dependent humans*. In Learning Factors in Substance Abuse, NIDA Research Monograph, USGPO, 44-61.
33. Hayashida, M., Alterman A.I., McLellan, A.T., O'Brien C.P. (1988). *Is inpatient alcohol detoxification justified?* In L. Harris (Ed.), Problems of Drug Dependence 1987, USGPO, 19-25.
34. O'Brien C.P., Childress A.R., McLellan A.T. (1990). *Conditioning factors may help to understand and prevent relapse in patients recovering from drug dependence*. NIDA Research Monograph, USGPO, 293-312.
35. Woody G.E., Luborsky, L., McLellan A. T. & O'Brien C.P. (1990). *Psychotherapy and counseling for methadone maintained opiate addicts: Results of research studies*. In L. Simon (Ed.) Psychotherapy in Drug Abuse Treatment, NIDA Research Monograph, USGPO, 9-23.
36. Childress A.R., McLellan A. T., Woody G.E. & O'Brien C.P. (1990). *Are there minimum conditions necessary for methadone maintenance to reduce IV drug use and IADS risk behaviors?* In C. Lukefeld & R. Pickens (Eds.) Review of Drug Abuse Treatment Research, NIDA Research Monograph, USGPO, 167-177.
37. McLellan A.T., Randall M., Joseph N., Alterman A.I. (1990) *Categorizing substance abusers using the ASI: Implications for evaluation and treatment*. NIDA Research Monograph Series, #105 USGPO, 227-235.
38. Milby J.B., Gentile M., Sims M.K., McLellan A.T., Woody G.E. and Haas N. (1990) *Methadone maintenance outcome as a function of detoxification fear: Preliminary findings*. NIDA Research Monograph Series, #105 USGPO, 589-590.
39. Woody, G.E., McLellan, A.T., O'Brien, J. Williams H., Dyanick, S., Metzger, D.S., DePhilippis, D., C.P., Druley, (1991) *HIV seroconversion and treatment status*. NIDA Research Monograph Series, #119, USGPO, 303.
40. Metzger, D.S., DePhilippis, D., Druley, P., O'Brien, C.P., McLellan, A.T., Williams, J., Navaline, H., Dyanick, S., Woody, G.E., (1991) *The impact of HIV testing on risk for AIDS behaviors*. NIDA Research Monograph Series, #119, 297.

41. Milby J.B., Gentile M., Sims M.K., Haas N., Huggins N., Hohman A., McLellan A.T. and Woody G.E. (1991) *Methadone maintenance outcome: Role of detoxification fear and its treatment*. NIDA Research Monograph Series, #119, 473.
42. McLellan A. T. & Alterman A.I. (1991) *Patient Treatment Matching: A Conceptual and Methodological Review With Suggestions for Future Research*. NIDA Research Monograph Series, #106, USGPO, 114-135.
43. O'Brien C.P., McLellan A.T. and Alterman A.I. (1991). *Effectiveness of treatment for substance abuse*. In S.G. Korenman and J.D. Barchas (Editors) Biological Basis of Substance Abuse. New York, Oxford Univ. Press, 487 - 510.
44. Alterman A.I., O'Brien C.P. and McLellan A.T. (1991). *Differential therapeutics for substance abuse*. In Frances R.J. and Miller S.I. (Eds.) Clinical Textbook of Addictive Disorders. New York, Guilford Press, 369 – 390.
45. Childress A.R., Ehrman R., McLellan A.T., O'Brien C.P. (1991). *Conditioned craving and arousal in cocaine addiction: A preliminary report*. In L. Harris Ed. Problems of Drug Dependence 1990, NIDA Research Monograph, USGPO, Series #106, 293-312.
46. Milby J.B., Huggins N., Hohmann A., McLellan A.T., Woody G.E. and Haas N. (1992) *Methadone maintenance rehabilitation outcome at six year follow-up: Treatment continuity effects*. NIDA Research Monograph Series, #132, 218.
47. Arndt I.O., Dorozynski L., Woody G.E., McLellan A.T., and O'Brien C.P. (1992) *Desipramine treatment for cocaine abuse in methadone-maintained patients*. Archives of General Psychiatry., 49:888-893.
48. Metzger, D.S., Woody, G.E., McLellan, A.T., O'Brien, C.P., & Navaline, H. (1992). *Twenty four month seroconversion rates and behavioral change among injection drug users in-and out-of-treatment*. NIDA Epidemiologic Trends in Drug Abuse,: Proceedings Community Epidemiology Work Group,. 503-506.
49. O'Brien, C.P., Alterman, A.I., and McLellan, A.T. (1992). *Developing and evaluating new treatments for alcoholism and cocaine dependence*. In Galanter, M. (ed.). Recent Developments in Alcoholism, Vol.10, pp.303-325, New York: Plenum, 149 -162.
50. McLellan A. T., Randall M., Metzger D., Alterman A.I., Cornish J., Woody G.E. and O'Brien C.P. (1992). *Appropriate expectations for substance abuse treatments: Can they be met?* In G.E. Edwards, J. Strang and J. Jaffe (Editors), Addiction Research and Treatment: Making the Science and Policy Connection Oxford, Oxford Univ. Press, 222 - 231.
51. O'Brien, C.P., McLellan, A.T., Alterman, A.I., and Childress, A.R. (1992). *Psychotherapy for cocaine dependence*. Ciba Foundation Press, London, 207-223.
52. McLellan A.T., Metzger D., Alterman A.I., Cornish J., Urschel, H. (1992). *How effective is substance abuse treatment - Compared to what?* In C.P. O'Brien and J. Jaffe (Editors) Advances in Understanding the Addictive States. N.Y., Raven Press, 231 – 252.

53. O'Brien C.P., Childress A.R., McLellan A.T. and Ehrman R.E. (1992). *A Learning Model of Addiction*. In CP O'Brien and J.Jaffe (Eds.) *Advances in Understanding the Addictive States*, Raven Press, N.Y. ,157 - 177.
54. Abellanas, L., Meyers, K., Metzger, D.S., & McLellan, A.T. (1993) *Latino IDUs: Do Their Risk Behaviors Differ From Those IDUs Of Other Racial Groups?* NIDA Research Monograph Series, #141, 216.
55. Fureman I., Alterman A.I., McLellan A.T., Zanis D. (1993) *A model for maintaining quality data with research interviews: The addiction severity index*. NIDA Research Monograph Series, #141, 184.
56. O'Brien C.P., Woody G.E. and McLellan A.T. (1995). *Enhancing the effectiveness of methadone using psychotherapeutic interventions*. In J. Blaine Ed. *Contemporary Treatment of Drug Dependence*, NIDA Research Monograph, USGPO, 5-18.
57. McLellan A.T. and Durell J. (1995). *Outcome Evaluation in Psychiatric and Substance Abuse Treatments: Conceptual and Methodological Considerations*. In L. Sederer (Editor), *Outcomes Assessment in Clinical Practice*, N.Y., Williams and Wilkins, 34 - 44.
58. McLellan, A.T., Metzger, D.S., Alterman, A.I., Woody, G.E., Durell, J., Weisner, C.M., O'Brien, C.P. (1995). *Is treatment for substance abuse "worth it"? Public health expectations, policy-based comparisons*. In: *Proceedings of Josiah Macy Conference on Medical Education*. Josiah Macy Foundation, New York, N.Y. ,165-211.
59. McLellan A.T., Belding M., McKay J.R., Zanis D. and Alterman A.I. (1996). *Can the outcomes research literature inform the search for quality indicators in substance abuse treatment?* In. M. Edmunds, R. Frank, M Hogan, D, McCarty, R. Robinson-Beale and C. Weisner (Eds.). *Managing Managed Care: Quality Improvement in Behavioral Health*. Washington, DC: National Academy Press, 271 - 311.
60. McLellan A.T. and Weisner C. (1996). *Achieving the public health potential of substance abuse treatment: Implications for Patient Referral, Treatment "Matching" and Outcome Evaluation*. In W. Bickel and R. DeGrandpre (eds.) *Drug Policy and Human Nature*. Wilkins and Wilkins, Philadelphia, 127 - 154.
61. Woody G.E., McLellan A.T. and O'Brien C.P. (1996). *Issues in substance abuse treatment: Lessons learned and future directions*. In Frances A. (Editor), *Substance Use and Mental Illness* New York, Plenum Press, 43-55.
62. Woody G.E., Metzger D.S., Navaline H., McLellan A.T. and O'Brien C.P. (1997) *Psychiatric Symptoms, risky behavior and HIV infection*. NIDA Research Monograph Series, #172, 156-170.
63. Luborsky L., Barber J.P., Siqueland L., McLellan A.T. and Woody G.E. (1997). *Establishing a therapeutic alliance with substance abusers*. In L. Onken et al. (Editors), *Beyond the therapeutic alliance: Keeping the drug dependent individual in treatment* . NIDA Research Monograph, USGPO, 233 - 244.

64. Arndt I.O., McLellan A.T., Metzger D.S., Woody G.E. and O'Brien C.P. (1997). *Substitution treatment and psychological services*. In D. Lewis et al. (Editors), *The Medical Prescription of Narcotics*. Bern, Switzerland, Hogrefe & Huber Publishers, 264 - 280.
65. Woody G.E., Luborsky, L., McLellan A.T. and O'Brien C.P. , Beck A.T., Mercer, D., (1997). *Variables in the psychotherapy of drug addicts*. *Weiner Zeitschrift für Suchtforschung*. 20 Nr. 3/4: 31-36.
66. Cacciola J., Alterman A.I., O'Brien C.P., McLellan A.T. (1997). *The Addiction severity index in clinical efficacy trials of medications for cocaine dependence*. NIDA Research Monograph. 175, 182 – 191.
67. Zanis, D. A., & McLellan, A. T. (1998). *Ensuring quality in the treatment of chemical dependency*. In, *Handbook of Quality Management in Behavioral Health*. Stricker, G., Troy, W., & Shueman, S. (Eds.) Plenum Press, 193-215.
68. McLellan A.T. and McKay J. *The treatment of addiction: What can research offer practice?* In Lamb S., Greenlick M. and McCarty D. (Eds.) *Bridging the Gap: Forging new partnerships in community-based drug abuse treatment*. 1998. Washington, DC: National Academy Press, 147 - 185
69. McLellan A.T. (1998). *Controlling the public health and safety problems of opiate use with methadone. Is the risk of diversion worth the potential benefits?* In W. Hall (editor) *Opioid Overdose: An International Symposium*. University of New South Wales Press, 105 - 115.
70. McLellan A.T. (2002). *Questioning the Effectiveness of Addiction Treatments: What is the Evidence?* In W.R. Miller and C.M. Weisner (Editors) *Changing Substance Abuse Through Health and Social Systems in New York*: Kluwer/Plenum, 29 - 45.
71. McLellan A.T. (2002). *Investing in Drug Abuse Treatment: A Discussion Paper for Policy Makers*. United Nations International Drug Control Programme. United Nations Press, 1 - 36.
72. McLellan A.T. (2002). *The role of Psychosocial Services in Drug Abuse Treatment: A Re-Examination of Psychosocial Services in Substance Abuse Treatment: On-Site vs. Off-Site Delivery Mechanisms*. In H. Waal and E. Haaga (Editors) *Maintenance Treatment in Addiction*. University of Oslo Press, Oslo, Norway. 267 - 295.
73. McLellan A.T., Kleber H.D., Lewis D. L. and O'Brien C.P. (2002) *The Case for Drug Dependence as a Chronic Medical Illness*. In Ruth Finkelstein and Sandra Ramos (Editors), *Manual for Primary Care Providers: Effectively Caring for Active Substance Users*. New York Academy of Medicine Press., New York, 189 - 211.
74. McLellan A.T. (2003), *Is addiction an illness – Can it be treated?* In Carra G. and Clerici M. (Eds), *Dual Diagnosis: Filling the Gap*. John Libbey Eurotext Publishers. Paris, 3 - 40.
75. Weisner, C., & McLellan, A. T. (2004) *Report of the Blue Ribbon Task Force on Health Services Research at the National Institute on Drug Abuse*.
<http://www.nida.nih.gov/about/organization/nacda/HSRReport.pdf>

76. McLellan A.T. (2007), *A Broken System: The Tangled Economics of Treatment*. In J. Hoffman and S. Fromke (Eds), *Addiction: Why Can't They Just Stop*. New York. Rodale Press, 167 - 203.
77. McLellan A.T. (2007) *Evaluating the Effectiveness of Addiction Treatment: What should a Drug Court team look for in a referral site?* In J. Kushner (Ed.), *National Drug Court Handbook*.

EDITORIALS, REVIEWS, CHAPTERS, INCLUDING PARTICIPATION IN COMMITTEE REPORTS (PRINT OR OTHER MEDIA); UNABLE TO OBTAIN COPIES

1. Gottheil, E., McLellan, A.T., Druley, K.A., Alterman, A.I. (1978) *Some relationships between experimental, theoretical, and clinical approaches to alcoholism*. In Gottheil et al. (eds.) *Addiction Research and Treatment: Converging Trends*, Pergamon Press, New York, 24 - 46.
2. McLellan, A.T., Druley, K.A.(1979) *Planning an alcohol detoxification program in a psychiatric hospital*. In Neigher, W. (Ed.), *CMHC Evaluation Source Book*, NIMH Press, Washington, 79 - 89.
3. McLellan, A.T., MacGahan, J., Druley, K.A (1980) *Drug abuse and psychiatric illness*. In E. Gottheil et al. (Eds.) *Substance Abuse and Psychiatric Illness*, Pergamon Press, New York, 12 - 22.
4. Woody, G.E., McLellan, A.T., Luborsky, L., O'Brien, C.P. (1981) *Effectiveness of two forms of psychotherapy with opiate dependent clients*. *Proceedings of the New York Academy of Sciences*, Vol. 362, 91-100, 85 - 97.
5. Luborsky, L., McLellan, A.T. (1981) *Matching of patients with types of psychotherapy: What is known and some designs for knowing more*. In Gottheil et al. (eds.) *Matching Patient Needs and Treatment Methods in Alcohol and Drug Abuse*, Chicago: Charles Thomas Pub., 11 - 22.
6. Gottheil, E., McLellan, A.T., Druley, K.A. (1981) *Laboratory research methodology in the evaluation of alcoholism treatment*. In Gottheil et al. (eds.) *Matching Patient Needs and Treatment Methods in Alcohol and Drug Abuse*, Chicago: Charles Thomas Pub., 38 - 49.
7. O'Brien, C.P., Terenius, L., Walstrom, A., McLellan, A.T. (1982) *Quantification of endogenous opiates in the cerebrospinal fluids of narcotic addicts*, *Proceedings of the N.Y.A.S.*, 377-387.
8. Woody, G.E., O'Brien, C.P., McLellan, A.T., Evans, B.D. (1982) *Use of anti-depressants along with methadone in maintenance patients*, *Proceedings of the N.Y.A.S.*, 120-127.
9. McLellan, A.T. (1983) *Predicting outcome from methadone maintenance: Role of patient factors*, in J. Cooper and S. Schnoll (Eds.) *A Review of Methadone Maintenance*, NIDA Research Monograph, USGPO, 234 - 246.
10. McLellan, A.T., Woody, G.E., Luborsky, L., O'Brien, C.P., and Druley, K.A. (1983) *Increased effectiveness of drug abuse treatment from patient-program matching*. *Problems of Drug Dependence 1982*, NIDA Research Monograph, #43. 67 - 73.

11. Skoloda, T., Griffiths, J., McLellan, A.T., Druley, K.A. (1983) *Criminality violence and response to drug abuse treatment*, in E. Gottheil, A.T. McLellan and K. Druley (eds) *Alcohol, Drug Abuse and Aggression*, Chicago: Charles C. Thomas, 104 - 111.
12. Woody, G.E., Persky, H.L., McLellan, A.T. (1983) *Hostility and anxiety in addicts: Endocrine correlates*. In E. Gottheil, A.T. McLellan and K. Druley (eds) Alcohol, Drug Abuse and Violent Behavior, Chicago: Charles C. Thomas Pub., 66 - 79.
13. McLellan, A.T., Woody, G.E. (1983) *The psychiatrically severe drug abuser: Identification, description and treatment implications*. In Glass, W.J. (Ed.) The Young Adult Chronic Patient, NIDA Research Monograph, #34, 106 - 120.
14. Woody, G.E., Luborsky, L., McLellan, A.T., O'Brien, C.P. (1983) *Psychotherapy for opiate addiction*. Problems of Drug Dependence 1982, NIDA Research Monograph, #43, 88 - 98.
15. McLellan, A.T., Griffiths, J. and Cacciola, J. (1983) *The Addiction Severity Index: Current Development*, in S. Krampitz (Ed.) *Psychiatric Nursing: Assessment Planning Intervention and Evaluation*, F.A. Davis Pub., New York, 210 - 223..
16. Woody, G.E., McLellan, A.T., O'Brien, C.P. *Drug abuse*. (1984) In A. Travis (Ed.) *Health and Medical Horizons - 1984*, New York, McMillan Ed. Co., 235-239.
17. Woody, G.E., McLellan, A.T., Luborsky, L. (1985) *Psychotherapy in the treatment of Substance Abusers*. In Frank B. (Ed.) Psychiatric Clinics of North America, Philadelphia, W.B. Saunders Co., 211 - 232.
18. Childress, A.R., McLellan, A.T. and O'Brien, C.P. (1985) *Nature and incidence of conditioned responses in a methadone-maintenance population*. Problems of Drug Dependence 1984, NIDA Research Monograph, USGPO, 56 - 70.
19. McLellan, A.T., Woody, G.E., Luborsky, L. (1985) *"Psychiatric Severity" as a predictor of outcome from substance abuse treatments*. In R.E. Meyer (Ed.) Psychiatric Aspects of Opiate Dependence, New York, Guilford Press, 19 - 24.
20. McLellan, A.T., Childress, A.R., and O'Brien, C.P. (1986) *Integrating behavioral extinction techniques with methadone maintenance: methodological issues and some preliminary data*. Problems of Drug Dependence 1985, USGPO, 86 - 99.
21. O'Brien C.P., Woody G.E., McLellan A.T. (1987) *Treatment Research. Drug Abuse and Drug Abuse Research: The Second Triennial Report to Congress*, U.S. Dept. Health and Human Services, USGPO, 17 - 21.
22. McLellan A.T., Alterman A.I., Parikh D., Zanis D., Bragg A. (1988) *Quantitative measure of substance abuse treatment: The Treatment Services Review (TSR)* In L. Harris Ed. Problems of Drug Dependence 1987, NIDA Research Monograph, USGPO, 47 - 53.
23. Woody G.E., McLellan A.T., O'Brien C.P., Persky H., Arndt I.O. (1988) *Hormone secretion in methadone dependent and abstinent patients*, In L. Harris (Ed.) Problems of Drug Dependence 1987, NIDA Research Monograph, USGPO, 45 - 50.
24. Alterman A.I., O'Brien C.P., McLellan A.T. (1990) *Differential therapeutics for substance abuse*. NIDA Research Monograph, USGP 79 - 84,.

25. Woody G.E., McLellan A. T. & O'Brien C.P. (1990) *Research on psychopathology and addiction: Treatment implications*. In C. Lukefeld & R. Pickens (Eds.) *Review of Drug Abuse Treatment Research*, NIDA Research Monograph, USGPO, 14 - 20.
26. McLellan, A.T. (1990) *Psychiatric Illness and Substance Abuse: Treatment Implications*, In The Third Triennial Report to Congress on Drug Abuse and Drug Abuse Research, DHHS Publication, in Press, 205 - 218.
27. McLellan A.T. (1990) *Patient-Treatment matching and outcome improvement in alcohol rehabilitation*. Chapter for the Institute of Medicine Report on Future Directions in Research and Treatment of Alcohol Dependence. National Academy of Science Pub., 167 - 188.
28. Woody G.E., McLellan A.T., Alterman A.I., O'Brien C.P. (1991) *Increasing collaboration between research and clinical practice in substance abuse treatment*. NIDA Research Monograph, USGPO, 82 - 100.
29. Woody G.E., McLellan A.T., O'Brien C.P., Arndt I.O. (1991) *Drug treatment programs as settings for pharmacology research*. NIDA Research Monograph, USGPO, 103 - 123.
30. Alterman A.I., Droba M., McLellan A.T. (1991) *Response of cocaine abusers to day hospital treatment*. In L. Harris Ed. *Problems of Drug Dependence 1990*, NIDA Research Monograph, USGPO, 12 - 28.
31. Milby J.B., Schumacher J., Khuder S., Huggins N., McLellan A.T., Woody G.E. and Haas N. (1992) *Addiction Severity status and treatment history of four methadone maintenance outcome groups*. In Epidemiologic Trends in Drug Abuse, NIDA Research Monograph, USGPO, 24 - 34.
32. Metzger D.S., Woody G.E., McLellan A. T., O'Brien C.P. and Navaline H. (1992) *Twenty four month seroconversion rates and behavioral change among injecting drug users in and out of treatment*. In Epidemiologic Trends in Drug Abuse, NIDA Research Monograph, USGPO, 45 - 67.
33. Metzger, D.S., Woody, G.E., McLellan, A.T., O'Brien, C.P., Meyers, K., & Navaline, H., (1994). *HIV Risk Reduction Among Intravenous Drug Users In- And Out-Of-Treatment: Stability Of Behavioral Change*. In L. Harris Ed. *Problems of Drug Dependence 1993*, NIDA Research Monograph, USGPO, 56 - 62.
34. Sarro, R., Metzger, D.S., Woody, G.E., Navaline, H., Oglesby, P., & Waskow, S. (1994). *Quantitative Changes in CD4 T-Lymphocytes in HIV+ Intravenous Drug Users*. In L. Harris Ed. *Problems of Drug Dependence 1993*, NIDA Research Monograph, USGPO, 211 - 217.
35. Woody, G.E., Metzger, D.S., McLellan, A.T., O'Brien, C.P., Meyers, K., Navaline, H., Dyanick, S., & Williams, J. (1994). *Three Year HIV Seroincidence Rates Among IDUS In- And Out-of-Treatment: Concordance Between Elisa And Polymerase Chain Reaction Test (PCR)*. In L. Harris Ed. *Problems of Drug Dependence 1993*, NIDA Research Monograph, USGPO, 102 - 134.
36. Zanis D., Metzger D., McLellan A.T. (1994) *Employment characteristics of methadone maintenance clients*. In L. Harris Ed. *Problems of Drug Dependence 1993*, NIDA Research Monograph, USGPO, 23 - 29.

37. Randall M., Zanis D., McLellan A.T. (1994) *Validity and reliability of the ASI in follow-up evaluations*. In L. Harris Ed. *Problems of Drug Dependence 1993*, NIDA Research Monograph, USGPO, 44 - 50.
38. Woody G.E., Luborsky L, McLellan A.T. and O'Brien C.P. (1994) *Individual psychotherapy for substance abuse*. In H. Kleber (Editor) Treatments for Non-Alcohol Substance Use Disorders. Am. Psychiat. Press. 100 - 120.
39. McLellan A.T., Alterman A.I., Woody G.E., Metzger D., McKay J. and O'Brien C.P. (1995) *Great Expectations: A review of the concepts and empirical findings regarding substance abuse treatment*. In Alcohol and Substance Dependence, Royal Task Force on Substance Dependence, London, England, 234 - 256.
40. Kranzler H.R. and McLellan A.T. (1995) *Pharmacotherapies for Alcoholism: Evolving Theoretical and Methodological Perspectives*. In H. Kranzler (Editor) Substance Abuse Treatment, Williams and Wilkins, New York, 45 - 61.
41. McLellan A.T. and Ball J.C. (1995) *Is Methadone Treatment Effective?* In R. Rettig (Editor) A Re-Evaluation of Federal Regulations on Methadone Treatment, Institute of Medicine Press, Washington D.C., 245 - 265
42. McLellan A.T., Woody G.E., Metzger D., McKay J., Alterman A.I. and O'Brien C.P. (1995) *Evaluating the Effectiveness of Treatments for Substance Use Disorders: Reasonable Expectations, Appropriate Comparisons*. In D. Fox (Editor) *The Milbank Foundation Volume on Health Policy Issues*, Milbank Foundation Press, New York, 65 - 78.
43. McLellan A.T. and Durell J. (1995) *Outcome Evaluation in the Treatment of Substance Dependence : Conceptual Rationale and Technical Methods* In W. Bickel (ed.) Drug Policy and Human Nature. Wilkins and Wilkins, Philadelphia, 105 - 125.
44. McLellan A.T. and Weisner C. (1996) *What substance abuse treatment needs: A way to show value to a demanding and skeptical public*. Treatment Today 34: 1 - 2.
45. Dennis M., McLellan A.T. and Huebner R. (1996) *Methodological issues in alcohol-related health services research*. in H. Perl (Editor) *Effectiveness and Outcomes in Alcohol Health Services Research*, NIAAA Health Services Monograph, Rockville, MD, 67 - 81.
46. McLellan A.T., Meyers K., Hagan, T. and Durell J. (1996) *Local data supports national trend in decline of substance abuse treatment system*. Connections 4 - 8.
47. Woody G.E., McLellan A.T., Cacciola J. and Metzger D.S. (1996) *Symptom Severity as a Predictor of Outcome* In Frances A. (Editor) Substance Use and Mental Illness New York, Plenum Press, 87 - 99.
48. Zanis, D. A., Belding, M. A., & McLellan, A. T. (1996) *The effects of retention on substance abuse treatment outcomes*. In, N. Miller & G. Collins (Eds.). Principles and Practices of Addiction Treatment. 126 - 134.
49. McLellan A.T., Hagan T.A., Meyers K., Randall M. and Durell J. 1997 *"Intensive" Outpatient Substance Abuse Treatment: Comparisons With "Traditional" Outpatient Treatment*. In Gottheil E. and Stimmel B. (Editors) Intensive Outpatient Treatment for the Addictions. New York. Haworth Medical Press. p. 57 - 84.

50. Alterman A.I., O'Brien C.P., McLellan A.T. and McKay J.R. (1997) *Treatments for substance abuse*. In Frances R.J. and Miller S.I. (Eds.) Clinical Textbook of Addictive Disorders New York, Guilford Press. 345 - 352.
51. Cacciola S, McLellan AT, Alterman AI, and Mulvaney FD: (1997) *A comparison of a self-administered ASI with the standard interview ASI*. NIDA Research Monograph, 123 - 129.
52. McKay J. and McLellan A.T. (1998) *Getting started: Research findings relevant to assessing substance abuse patients and developing an initial treatment plan*. In W.R. Miller and N. Heather (Eds.) Advances in Alcoholism Treatment. 69 - 74.
53. McLellan A.T. and McKay J. (1998) *Components of successful addiction treatment: What does research say?* In Graham A.W. and Schultz T. (Eds.) Principles of Addiction Medicine (Second Edition) University of Chicago Press. Chicago. 63 - 71.
54. McLellan A.T. *Demographic differentials in the demand for alcohol and illicit drugs*. In Chaloupka F., Grossman M., Bickel W., and Saffer H. (Eds.) The Economic Analysis of Substance Use and Abuse, Univ. of Chicago Press. Chicago. 1999.
55. Meyers, K. & Hagan, T. A. (1998). *Immediate and comprehensive adolescent assessment*. Community Assessment Center Manual, Office of Juvenile Justice and Delinquency Prevention, US Department of Justice, Washington, DC. 58 - 66.
56. Moos, R.H., Finney, J., Cannon D., Finkelstein A., McNicholas L., McLellan A.T. and Suchinsky R. (1998) *Patient Characteristics at Treatment Baseline*. In R.H. Moos (Editor) Outcomes Monitoring for Patients With Substance Use Disorders. Veterans Administration Press., Washington D.C., 18 - 36.
57. McLellan A.T. and McKay J. (1999) *Monitoring the effectiveness of alcohol treatments: Strategies for linking performance measures to outcomes*. Frontlines. June, 1999. NIH Press. Bethesda MD. 39 - 44.
58. Weisner C.M. and McLellan A.T. (1999) *Developing performance indicators of service outcomes*. In D.W. Garnick, F. McCorry, M. Chalk M., and Cotter F. (Eds) Improving Performance Measurement by Managed Care Plans for Substance Abuse. Center for Substance Abuse Treatment, Washington D.C. 65 - 72.
59. Zanis DA, McLellan AT. *Ensuring quality in the treatment of chemical dependency*. In: Stricker G, Troy WG, al. e, eds. Handbook of quality management in behavioral health Issues in the practice of psychology. New York: Kluwer Academic/Plenum; 2000:193-215
60. McLellan A.T. (2002) *The outcomes movement in substance abuse treatment: Comments, concerns and criticisms*. In J. Sorenson et al. (Editors) Drug Abuse Treatment Through Collaboration: Practice and Research Partnerships That Work. Washington, D.C. American Psychological Association Press. 58 - 63.
61. Carise D., Gurel O., Kendig C., McLellan A.T. (2002) *Integrating Assessment Technology with Treatment: The DENS Project*. In J.L. Sorenson, R. Rawson, J. Gudyish and J.E. Zweben (Eds.) Drug Abuse Treatment Through Collaboration: Practice and Research Partnerships That Work. American Psychological Association Press. Washington DC. 67 - 98.

62. McLellan A.T. and McKay J. (2002) *Components of successful addiction treatment: What does research say?* In Graham A.W. and Schultz T. (Eds.) Principles of Addiction Medicine (Third Edition) University of Chicago Press. Chicago. 20 - 32.
63. McLellan A.T., Carise D. and Kleber H.D. (2003) *Problems with the national addiction treatment infrastructure.* In. J. Jaffe and D. Rosenbloom (Eds) Contemporary Issues in Addiction Treatment. Haworth Press.
64. Meyers K. and McLellan A.T. (2004) *The American Treatment System for Adolescent Substance Abuse: Formidable Challenges, Fundamental Revisions and Mechanisms for Improvements.* In Seligman M.E.P. and Evans D. L. (Editors) *Current Issues in Adolescent Health*. Oxford University Press. Oxon, England, 210 - 244.
65. Uchtenhagen A., Simpson D.D., Farrell M., Ali R., Mattick R. and McLellan A.T. (2004) *World Health Organization Special Report – Methadone as an Essential Medicine.* <http://www.who.int/medicines/organization/expcom05add.shtml>
66. McLellan A.T. (2005) *The status of the United States Treatment System: Implications for Evidence Based Treatments.* In Miller, W. R., & Carroll, K. M. (Eds.). Rethinking substance abuse: What the science shows and what we should do about it. New York: Guilford Press. 146 - 157.
67. McLellan A.T. and McKay J. (2002) *Components of successful addiction treatment: What does research say?* In Graham A.W. and Schultz T. (Eds.) Principles of Addiction Medicine (Third Edition) University of Chicago Press. Chicago. 2002.
68. McLellan, A.T. (2007) *Evolution in Addiction Treatment Concepts and Methods - But Not in the Delivery System.* In M. Galanter and H. Kleber Handbook of Addiction Medicine.
69. Mee-Lee D., McLellan A.T. and Miller S.D. (2007) *Delivering What Works.* In S.D. Miller Heart and Soul of Change 2nd Edition. Macmillan Press, New York.
70. McLellan A.T. and McKay J. (2009) *Integrating Evidence-Based Components into a Functional Continuum of Addiction Care.* In Graham A.W. and Schultz T. (Eds.) Principles of Addiction Medicine (Third Edition) University of Chicago Press. Chicago. 2008.
71. McLellan A.T., Cacciola J., Alterman A.I. (2008) *The Addiction Severity Index (ASI)* In Hassin D. & Kranzler H. (Eds) *Encyclopedia of Drugs, Alcohol and Addictive Behavior – Third Edition.* Gale Press., Farmington MI. p.67.
72. McLellan A.T. (2008) *Changing the Paradigm: Transforming Delivery of Care.* In Marc Fishman (Ed.) Achieving Treatment Success in Alcohol Dependence: Integrating Pharmacologic and Psychosocial Approaches. American Society of Addiction Medicine Press. Washington D. C. p. 11 - 19.
73. McLellan, A.T. (2007) *Evolution in Addiction Treatment Concepts and Methods - But Not in the Delivery System.* In M. Galanter and H. Kleber Handbook of Addiction Medicine.

- b. Supply four (4) copies of any reports, memoranda or policy statements you prepared or contributed in the preparation of on behalf of any bar association, committee, conference, or organization of which you were or are a member. If you do not have a copy of a report, memorandum or policy statement, give the name and address of the organization that issued it, the date of the document, and a summary of its subject matter.

None

- c. Supply four (4) copies of any testimony, official statements or other communications relating, in whole or in part, to matters of public policy or legal interpretation, that you have issued or provided or that others presented on your behalf to public bodies or public officials.

TESTIMONY:

Note: Copies of testimony submitted are contained in TAB C.

- 1. Rogue Online Pharmacies: The Growing Problem of Internet Drug Trafficking: Hearing before the Committee on the Judiciary, Senate, 110th Cong., 1 (May 16, 2007).**
 - 2. Performance and Outcome Measurement in Substance Abuse and Mental Health Programs: Hearing before the Subcommittee on Substance Abuse and Mental Health Services of the Committee on Health, Education, Labor, and Pensions, Senate, 108th Cong., 2 (July 20, 2004).**
 - 3. Measuring the Effectiveness of Drug Addiction Treatment: Hearing before the Subcommittee on Criminal Justice Drug Policy and Human Resources of the Committee on Government Reform, House of Representatives, 108th Cong., 2 (March 30, 2004).**
 - 4. Causes and Consequences of Alcohol Use: Hearing before the Committee on Governmental Affairs, Senate, 100th Cong., 2 (June 16, 1988).**
- d. Supply four (4) copies, transcripts or recordings of all speeches or talks delivered by you, including commencement speeches, remarks, lectures, panel discussions, conferences, political speeches, and question-and-answer sessions. Include the date and place where they were delivered, and readily available press reports about the speech or talk. If you do not have a copy of the speech or a transcript or recording of your remarks, give the name and address of the group before whom the speech was given, the date of the speech, and a summary of its subject matter. If you did not speak from a prepared text, furnish a copy of any outline or notes from which you spoke.

I have attached copies of PowerPoint slides for 116 presentations I have given over the past 5 – 6 years (PowerPoint at TAB D). The dates on those presentations give an indication of the year and approximate date of last use. While this provides an essentially complete description of all topics, it does not account for the date and time of each presentation. Each presentation has been delivered multiple times and to multiple audiences (see below). I simply have not kept records due to the volume of requests I receive (about 3 – 5 per month for the past 25 years).

In the interests of providing a full account of *what* I have presented and *to whom* I have presented, I offer the following. All talks and presentations have focused upon the research done by myself and my colleagues and this work can be divided into four themes: scientific studies evaluating the effectiveness of various types of alcohol and other drug treatments; scientific studies evaluating the efficiency and public value of various types of treatment financing, purchasing and regulatory systems; an historical and conceptual review of how addiction and addiction treatment have been conceptualized and treated – emphasizing the differences between an acute and a continuing care perspective; and finally, translational research studies helping to bring scientific forms of addiction treatment into contemporary treatment settings and systems.

There are also only four kinds of audiences for these talks. I estimate that about 65% of the talks given have been to researchers and scientists in scientific meetings and academic colloquia, both nationally and internationally. Addiction treatment providers and provider organizations represent about 20% of the audiences to whom I have spoken. The remaining audiences have been groups of city, state and national legislators (about 50 of these groups) and to groups of parents whose children have been affected by addiction. Of course these are not exact figures or times but they represent my best estimates in the absence of official records.

As can be seen from the attached PowerPoint presentations, I have discussed topics entirely in terms of the experimental evidence (from clinical, health services and policy research studies done by me and my colleagues (all of these are published in the above cited papers) as well as by other researchers. The specific content of these talks has evolved over the years with the increase in research studies and available evidence. Importantly these talks do not present my subjective opinions or views on these topics. All talks for the past 25 years have been reports of research studies and other factual data from the published papers presented above.

What follows are specific titles of these presentations with descriptions of content. As indicated, each of these talks has been given to multiple audiences and multiple times over the years and I do not have records on the exact dates or even the number of times each has been presented.

1. **Bridging the Treatment-Research Gap: ASI-Based Procedures Ready for Use in Your Program** – Presents research done by the Institute of Medicine on the gap between the known effective elements of addiction treatment and the types of care

provided by the treatment system. Concludes with practical suggestions for how to implement evidence-based evaluation and assessment at the individual program level.

2. **Bridging the Treatment Research Gap: Evidence-Based Procedures Ready for Use in Your Program** - Presents research done by the Institute of Medicine on the gap between the known effective elements of addiction treatment and the types of care provided by the treatment system. Concludes with practical suggestions for how to implement evidence-based therapies and interventions at the individual program level.
3. **Substance Abuse Treatment: What is It? Why Does It Seem Ineffective/Lessons Learned from Research in Other Fields of Healthcare** - Presents research done by myself and colleagues on treatment delivered in an “acute care” vs. a “chronic care” model, used by the rest of healthcare. Illustrates the conceptual differences and differences in clinical and evaluation methods.
4. **Drug Abuse Treatment, What are the Goals? How are they Measured? Are They Appropriate?** - Presents research done by myself and colleagues on the organization, financing and management of addiction treatment. Illustrates the conceptual differences and differences in clinical methods.
5. **Substance Abuse Treatment: What Works? Why Does Treatment seem so Ineffective? Lessons from Research in Other Fields of Healthcare** - Presents research done by the Institute of Medicine, myself and colleagues on various types of medications, therapies and interventions. Illustrates the potential effectiveness of addiction treatment but also the conceptual, and organizational barriers to delivering more effective care.
6. **Don’t Adapt Evidence Based Practices: Adapt the System!** - Presents treatment system barriers to the implementation of scientific (evidence-based) treatments. Concludes with organizational and management procedures used in business research to address these barriers.
7. **Re-Considering Addiction: Implications from a Chronic Care Perspective** - Presents research done by myself and colleagues on treatment delivered in an “acute care” vs. a “chronic care” model, used by the rest of healthcare. Illustrates the conceptual differences and differences in clinical and evaluation methods.
8. **The Future is Now! New Options for Alcohol Treatment** - Presents research done by the Institute of Medicine, myself and colleagues on various types of medications, therapies and interventions. Illustrates the potential effectiveness of these new forms of addiction treatment but also the conceptual, and organizational barriers to delivering more effective care.
9. **Matching Patients and Treatments: The Importance of Treatment Factors** - Presents research done by myself and colleagues showing increased effectiveness from matching particular types of medications, therapies and interventions to specific types of patients.

10. **Re-Considering the Evaluation of Addiction Treatment: From Post-Treatment Follow-up to “Recovery Monitoring”** - Presents research done by myself and colleagues on the differences in outcomes and the improved clinical information gained when treatment is delivered and evaluated in a “continuing care” model.
11. **Re-Considering Addiction: Clinical Questions to Guide New Research** - Presents research done by the Institute of Medicine, myself and colleagues on various types of medications, therapies and interventions. Illustrates the potential effectiveness of addiction treatment but also the need for new research on the conceptual, and organizational barriers to delivering more effective care.
12. **Is Substance Abuse Treatment Effective...Why Doesn't it Seem That Way?** - Presents research done by myself and colleagues on treatment delivered in an “acute care” vs. the “continuing care” model, used by the rest of healthcare. Illustrates the conceptual differences, perceived outcome differences and differences in clinical and evaluation methods from these two approaches.
13. **Is Addiction Treatment Effective? Implications From a Continuing Care Perspective** - Presents research done by myself and colleagues on treatment delivered in an “acute care” vs. a “chronic care” model, used by the rest of healthcare. Illustrates the conceptual differences and differences in clinical and evaluation methods.
14. **Evaluation of CASAWORKS for Families** – This is a report of a single large research study of a comprehensive addiction treatment intervention delivered to unemployed, addicted women receiving TANF benefits. Results are discussed in terms of the added public value to integrating addiction treatment into the context of other health and human services for multiple problem populations such as TANF recipients.
15. **Evaluation of CASAWORKS for Families** – Same as above – interim findings.
16. **Evaluation of CASAWORKS for Families** – Same as above – interim findings.
17. **Substance Abuse Treatment: What is It? Why Does it Seem Ineffective? Lessons from Research in Other Fields of Healthcare** – This is a fundamental discussion of the concepts, methods, “active ingredients” and results from contemporary addiction treatments. This talk has been presented to many audiences outside of the addiction field to provide basic information about the nature, structure, function and reasonable expectations from addiction treatment.
18. **What is Recover? Can We Measure It?** – The most successfully treated cases of addiction do not simply stop drug or alcohol use, they change their relationships with family and society and they become more fully functioning citizens. The combination of abstinence as well as better health, social function and personal responsibility has been characterized as “Recovery” but because of its complex nature it has not had a standard

operational definition that would enable it to be measured and studied and promoted. This talk represents the work of the Betty Ford Institute to do that consensus definition.

19. **Center for Organization and Management in Addiction Treatment** – This is a description of a University of Pennsylvania and Treatment Research Institute research center that has used the principles of better business practices to help the addiction treatment system address the financing, management, regulatory and purchasing barriers to improving treatment quality and effectiveness.
20. **Extra-treatment Factors in the Course of Alcohol Problems: Treated and Untreated Populations** – This talk presents a review of research by myself and my colleagues on the personal, family, health and social factors that can modify and ultimately determine the effectiveness of contemporary addiction treatments.
21. **The Drug Evaluation Network System: DENS** – This is a talk describing the results of a large multi-state study that characterized the nature of the US treatment system and the patients who entered that system between 1999 – 2004. The study was terminated but provided the best data available to date on the fundamental aspects of the US treatment system and the problems presented by the patients who entered that system each year.
22. **The Drug Evaluation Network System: DENS** – Same as above – interim findings.
23. **Engaging Detoxification Patients into Continuing Rehabilitation: Performance-based Contracting** – This talk describes the findings from a state-wide (Delaware) study of purchasing incentives applied at the treatment program level to promote the continuation of addiction care following simple detoxification. The intervention was not effective and provides an important lesson on the use of incentives in healthcare.
24. **Issues That Will Affect Addiction Treatment and Presumptuous Recommendations** – This was a discussion of contemporary issues outside of the addiction treatment system that will nonetheless affect the delivery of care. They included the emergence of managed care, the reliance on residential treatment by the criminal justice treatment, the absence of agreed upon standards of effectiveness, and the increased number of effective medications available for the treatment of alcohol and other drug problems. The presentation concludes with a discussion about evidence based solutions to prepare the field for these forces.
25. **Program of Research to Integrate Substance Use Issues into Mainstream Healthcare.** - This is a description of a University of Pennsylvania and Treatment Research Institute research center that has worked with the four largest primary care medical societies to show them how unhealthy levels of alcohol and other drug consumption have adversely affected the treatment, costs and outcomes of treatments for other chronic illnesses such as hypertension, asthma, diabetes, various cancers, sleep problems and chronic pain. The research presented medical solutions to controlling unhealthy substance use that would improve the effectiveness of treatments for other chronic illnesses such as those above.

26. **Re-Thinking Addiction Treatment?** - Presents research done by me and my colleagues on treatment delivered in an “acute care” vs. a “chronic care” model, used by the rest of healthcare. Illustrates the conceptual differences and differences in clinical and evaluation methods from approaching addiction as a continuing care condition; and discusses the system changes required to implement that form of care.
27. **What’s Wrong With Addiction Treatment?** – This is basically the same talk as the one just described but with a somewhat different title.
28. **NIDA Health Services Research Task Force Report and Recommendations.** – This is a report of a commission I co-chaired on behalf of the NIDA that discussed suggestions for improving the breadth and public health return from NIDA health services research.
29. **Measurement Challenges In Addiction Treatment.** – There have not been standard, agreed upon measures of patient severity at treatment admission or treatment effectiveness within the addiction treatment system. This talk reviews the research from many researchers in the addiction field and suggests common measurement domains and methods that might bring standardization to the field.
30. **Is Addiction Treatment Effective? Implications From a Chronic Care Perspective -** Presents research done by me and my colleagues on treatment delivered in an “acute care” vs. a “chronic care” model, used by the rest of healthcare. Illustrates the conceptual differences and differences in clinical and evaluation methods from approaching addiction as a continuing care condition; and discusses the system changes required to implement that form of care.
31. **Is Addiction Treatment Effective?** – Same as above with a slightly different title.
32. **Bridging the Treatment Research Gap - We May Have to Start With a Rope Bridge!** – This is a presentation discussing the results of the Institute of Medicine report on the gap between the known effective methods of treating addiction and the methods that are most widely used. The presentation discusses the organizational and financing barriers to upgrading the treatment system according to IOM guidelines.
33. **REAL WORLD MATCHING – Who/What Should be Matched to What/Where??** – Presents the results of 5 studies done by me and my colleagues showing increased effectiveness of matching specific types of treatments to particular types of patients.
34. **Drugs VIA the Internet, Nature, Extent, Implications, Online “Pharming”** Presents the results of a series of studies done by me and my colleagues investigating the sale of pharmaceutical drugs over the internet without a prescription.
35. **What’s Wrong With Addiction Treatment: What Could Help?** - This is a presentation discussing the results of the Institute of Medicine report on the gap between the known effective methods of treating addiction and the methods that are most widely

used. The presentation discusses the organizational and financing barriers to upgrading the treatment system according to IOM guidelines.

36. **Effectiveness, Quality, Performance: What's the Difference? & How do you use them?** – Presents standard definitions for these three terms and why they are different. The presentation continues with a discussion of how to measure each and why they are complementary but not identical. The presentation concludes with a description of a performance management system used by several state treatment systems.
37. **What's Wrong With Addiction Treatment: What Could Help?** – This is another version of the talk about evidence based treatments, delivered in a continuing care model and monitored continuously as is now done in the treatment of other chronic illnesses.
38. **Changing Addiction Treatment: Moving From Placement to Management Thinking** - This is another version of the talk about evidence based treatments, delivered in a continuing care model and monitored continuously as is now done in the treatment of other chronic illnesses.
39. **Changing Addiction Treatment: Moving From Placement to Management Thinking.** Same as above.
40. **Re-Considering Addiction Treatment- Have We Been Thinking Correctly?** – Same as above.
41. **Re-Considering Addiction Treatment- How Can Treatment be More Accountable and Effective?** - This is another version of the talk about evidence based treatments, delivered in a continuing care model and monitored continuously as is now done in the treatment of other chronic illnesses. Here the emphasis is on the development of management systems derived from other industries to monitor the quality and effectiveness of care.
42. **A New Treatment Model?- Lessons from Physician Health Plans.** This presentation discusses the results of a ten year study of 1,000 addicted physicians participating in Physician Health Programs in 16 states. Findings show outstanding effectiveness and point to a type of continuing care treatment that has not been available to non-physicians.
43. **Improving S/A Outcomes: Moving Toward Medical Culture** – This presentation discusses the benefits to general medicine, and particularly the treatment of chronic illness, from addressing unhealthy substance use. In a corresponding manner the presentation discusses the potential benefits to addicted patients from incorporating more medical care and medications for addiction and psychiatric problems.
44. **Re-Considering Addiction Treatment: Have We Been Thinking Correctly? (Does Anything Work?)** - This is another version of the talk about evidence based treatments, delivered in a continuing care model and monitored continuously as is now done in the treatment of other chronic illnesses. Here the emphasis is on the development

of management systems derived from other industries to monitor the quality and effectiveness of care.

45. **Re-Considering Addiction Treatment: How Can Treatment be More Accountable and Effective? A Business Perspective.** - This is another version of the talk about evidence based treatments, delivered in a continuing care model and monitored continuously as is now done in the treatment of other chronic illnesses. Here the emphasis is on the development of management systems derived from other industries to monitor the quality and effectiveness of care.
46. **Re-Considering Addiction Treatment: Implications From a Chronic Care Perspective.** This is another version of the talk about evidence based treatments, delivered in a continuing care model and monitored continuously as is now done in the treatment of other chronic illnesses.
47. **Is Substance Abuse Treatment Effective...Lessons From Research in Other Fields of Healthcare.** - This is another version of the talk about evidence based treatments, delivered in a continuing care model and monitored continuously as is now done in the treatment of other chronic illnesses.
48. **Re-Considering Addiction Treatment: Have We Been Thinking Correctly?** - Same as above
49. **Re-Considering Addiction Treatment: How Can Treatment be More Accountable and Effective? A Business Perspective.** This is another version of the talk about evidence based treatments, delivered in a continuing care model and monitored continuously as is now done in the treatment of other chronic illnesses. Here the emphasis is on the development of management systems derived from other industries to monitor the quality and effectiveness of care.
50. **Re-Considering Addiction Treatment: How Can Treatment be More Accountable and Effective? A Business Perspective** Same as above – interim findings
51. **Re-Considering Addiction Treatment: Have We Been Thinking Correctly? (Kaiser)**
- This is another version of the talk about evidence based treatments, delivered in a continuing care model and monitored continuously as is now done in the treatment of other chronic illnesses. Here the emphasis is on tailoring the lessons learned in other parts of the addiction treatment system to the Kaiser Permanente system.
52. **Substance Abuse Treatment: What is it? Why Does it Seem Ineffective?** - This is a fundamental discussion of the concepts, methods, “active ingredients” and results from contemporary addiction treatments. This talk has been presented to many audiences outside of the addiction field to provide basic information about the nature, structure, function and reasonable expectations from addiction treatment.

53. **TRI : Yesterday, Tomorrow & TODAY.** – This is a presentation describing the structure and research portfolio of my non-profit research institute. It describes the results of our various studies over the years.
54. **Re-Considering Addiction Treatment: Implications From a Chronic Care Perspective** - This is another version of the talk about evidence based treatments, delivered in a continuing care model and monitored continuously as is now done in the treatment of other chronic illnesses. Here the emphasis is on the development of management systems derived from other industries to monitor the quality and effectiveness of care.
55. **What's Wrong With Addiction Treatment: What Could Help?** - This is another version of the talk about evidence based treatments, delivered in a continuing care model and monitored continuously as is now done in the treatment of other chronic illnesses. Here the emphasis is on the development of management systems derived from other industries to monitor the quality and effectiveness of care.
- e. List all interviews you have given to newspapers, magazines or other publications, or radio or television stations, providing the dates of these interviews and four (4) copies of the clips or transcripts of these interviews where they are available to you.

TRANSCRIPTS for TELEVISION INTERVIEWS:

Note: actual transcripts are at E1

1. **Teens' prescription drug abuse via the Internet is growing problem**
CBS News Transcripts, May 17, 2007 Thursday, 496 words
2. **Senate holds hearings on drugs being available over the Internet**
CBS News Transcripts, May 16, 2007 Wednesday, 454 words
3. **Detox not enough, conference told**
CBC News, July 10, 2007 Tuesday 3:28 PM GMT, 408 words
4. **CHANGING LIVES**
Public Affairs Television, "Bill Moyers", March 30, 1998

INTERVIEW AVAILABLE ON VIDEO

Four copies of the series tapes are provided to the Committee and are labeled TAB E-2.: VIDEO

1. **Hoffman, J., & Froemke S. (Producers). (2007). Addiction [Motion Picture]. United States: HBO Documentary Films.**

I was interviewed as part of the HBO television series “Addiction.” I served as Scientific Adviser to the series and appeared briefly describing some promising treatment methods from my research findings.

INTERVIEWS , QUOTES AND ATTRIBUTIONS IN PRINT

I have not kept records of interviews that resulted in print but a lexis-nexus search has been conducted. A list of cites follows and the actual text of the interviews or quotes and attributions are attached at TAB E-3.

1. TREATING DRUG-ADDICTED DOCTORS IS GOOD MEDICINE
Sun-Sentinel (Fort Lauderdale, Florida), March 3, 2009 Tuesday, JEWISH JOURNAL; Pg. 28, 949 words, Staff report
2. Wanted: Chemical dependency counselors
San Angelo Standard-Times (Texas), February 19, 2009 Thursday, OPINION/VIEWPOINTS/", 1139 words, ERIC A. SANCHEZ Special to the Standard-Times
3. Bare-bones rehab leads addicts on sober road
The Denver Post, February 15, 2009 Sunday, A SECTION; Pg. A-01, 1888 words, Nancy Lofholm The Denver Post
4. Most overdose fatalities in W. Virginia due to nonmedical use of pharmaceuticals
Reuters Health Medical News, December 9, 2008 Tuesday 9:00 PM EST, PUBLIC HEALTH, 339 words
5. HARFORD PROGRAM AIMS TO HELP INMATES STAY OUT; INNOVATIVE EFFORT PROVIDES DRUG TREATMENT, MENTAL HEALTH CARE AND TRANSPORTATION
The Baltimore Sun, November 4, 2008 Tuesday, LOCAL; Pg. 3A, 1240 words, David Kohn, david.kohn@baltsun.com
6. What Addicts Need; Addiction isn't a weakness; it's an illness. Now vaccines and other new drugs may change the way we treat it.
Newsweek, March 3, 2008, COVER STORY: SCIENCE; Science; Pg. 36, 3939 words, By Jeneen Interlandi; With Raina Kelley
7. On Florida Coast, Addicts Find Home in an Oasis of Sobriety
The New York Times, November 16, 2007 Friday, Section A; Column 0; National Desk; Pg. 1, 1650 words, By JANE GROSS; Terry Aguayo contributed reporting from Miami.
8. So, What Made Me an Addict? Experts Debate Whether Disease or Defect Is to Blame
The Washington Post, August 28, 2007 Tuesday, Correction Appended, HEALTH; Pg. HE01, 1931 words, Maia Szalavitz; Special to The Washington Post

9. Track money flow to stop movement of addictive drugs
San Jose Mercury News (California), May 28, 2007 Monday, OPINION, 807 words, By Keith Humphreys
10. Panel Hears of E-Pharmacies Selling Narcotics Without Prescriptions
WASHINGTON INTERNET DAILY, May 17, 2007 Thursday, TODAY'S NEWS, 690 words
11. ONLINE PHARMACIES AND DRUG TRAFFICKING
CQ Congressional Testimony, May 16, 2007 Wednesday, CAPITOL HILL HEARING TESTIMONY, 1342 words
12. 'Rogue' Internet Pharmacies Fueling Rx Abuse, Panel Told
Washingtonpost.com, May 16, 2007 Wednesday 5:44 PM EST, 1024 words, Brian Krebs, washingtonpost.com Staff Writer, washingtonpost.com
13. HEALTHCARE ACCESS; National effort to improve addiction treatment quality moves forward Law & Health Weekly, December 30, 2006, EXPANDED REPORTING; Pg. 294, 552 words
14. National Effort to Improve Addiction Treatment Quality Moves Forward; Advancing Recovery Partnerships Working to Improve Addiction Treatment Success Rates
Ascribe Newswire, December 5, 2006 Tuesday 2:06 AM Eastern Time, 966 words
15. Treatment gains on research: New and effective medications that suppress drug cravings have been a huge advancement in the treatment of substance abusers. Last week was National Addictions Awareness Week
Edmonton Journal (Alberta), November 26, 2006 Sunday, SUNDAY READER; Pg. F5, 1534 words, William Celis, Freelance
16. PSYCHIATRIST: TODAY'S ADDICTION TREATMENTS OFTEN SHORT-SIGHTED
US States News, October 10, 2006 Tuesday 4:54 AM EST, 303 words, US States News
17. BRAIN RESEARCH IS KEY TO HOPE; NEW DRUGS, NEW APPROACH FUEL MAJOR EFFORTS FOR MANY TO HAVE PRODUCTIVE LIVES
Wisconsin State Journal (Madison, Wisconsin), August 21, 2006 Monday, FRONT; Pg. A1, 1208 words, WILLIAM CELIS Public Access Journalism
18. A CLOSER LOOK: ALCOHOLISM; All part of managing a disease
Los Angeles Times, August 14, 2006 Monday, HEALTH; Features Desk; Part F; Pg. 1, 923 words, Susan Brink, Times Staff Writer
19. Research offers new hope
The Myrtle Beach Sun-News (South Carolina), August 10, 2006 Thursday, A; Pg. 1, 1710 words, William Celis, Public Access Journalism

20. Treatment catching up with brain and genetic research
Centre Daily Times (State College, PA), August 8, 2006 Tuesday, A; Pg. 1, 174 words,
William Celis, McClatchy Newspapers
21. Physician substance abusers spur Tx research; Clinical report
Family Practice News, June 15, 2006, Pg. 42(1), 706 words, Kirn, Timothy F.
22. Physician programs inspiring substance abuse treatment efforts; care and treatment;
Statistical Data Clinical Psychiatry News, June 1, 2006, Pg. 44(1), 709 words, Kirn,
Timothy F.
23. The Real OC
Salt Lake City Weekly (Utah), May 26, 2005 Thursday, Pg. 22, 4691 words
24. Fighting the stigma linked to addiction; Summit urges better treatment of costly social ills
The Herald-Sun (Durham, NC), April 18, 2005 Monday, DURHAM; Pg. B1, 1075 words,
JIM SHAMP jshamp@heraldsun.com; 419-6633
25. Just say ... nothing? The parental 'drug talk' fades
Christian Science Monitor (Boston, MA), March 7, 2005, Monday, USA; Pg. 01, 1063
words, By Alexandra Marks Staff writer of The Christian Science Monitor
26. Rap on drug treatment called unfair
Salt Lake Tribune (Utah), September 25, 2003, Thursday, Final; Pg. B3, 422 words, Jacob
Santini, The Salt Lake Tribune
27. Penn prof is creating a guide to addiction treatment
The Philadelphia Inquirer, SEPTEMBER 15, 2003 Monday CITY-D EDITION,
FEATURES HEALTH & SCIENCE; Pg. C03, 464 words, Stacey Burling INQUIRER
STAFF WRITER
28. IT TAKES A BIT MORE THAN WILLPOWER
Charlotte Observer (North Carolina), June 23, 2003 Monday ONE-THREE EDITION
Correction Appended, HEALTH; KAREN GARLOCH - CHECKUP; Pg. 1E, 512 words,
KAREN GARLOCH, Staff Writer
29. Teens get the word on drug culture
The Philadelphia Tribune, May 13, 2003, Vol. 119; No. 51; Pg. 4B, 770 words, Jones,
Ayana
30. Your Brain on Alcohol
US News & World Report Special Issue, January 1, 2003 Wednesday, 3525 words, Susan
Brink
31. Staying Clean

The New York Times, February 10, 2002 Sunday, Section 6; Column 1; Magazine Desk; Pg. 34, 7477 words, By Peggy Orenstein; Peggy Orenstein is a contributing writer for the magazine and the author of "Flux: Women on Sex, Work, Love, Kids and Life in a Half-Changed World."

32. Drug treatment gets big boost, October 5, 2000, Thursday,, 431 words
33. CITY REPORT: Help me complete a mission
Call and Post (Cleveland), April 23, 1998, Vol. 83; No. 17; Pg. 2A, 318 words, Patmon, Bill
34. MOYERS STAYS 'CLOSE TO HOME' IN ADDICTION SERIES
The Commercial Appeal (Memphis, TN), March 29, 1998, SUNDAY,, 879 words, Tom Walter The Commercial Appeal
35. THE TYRANT OF YOUR LIFE'; ADDICTION FOCUS OF PBS SERIES
Plain Dealer (Cleveland, Ohio), March 29, 1998 Sunday, FINAL / ALL, LIVING; Pg. 1J, 1663 words, By KAREN R. LONG; PLAIN DEALER REPORTER
36. Coming to terms with addiction; Bill Moyers examines what may be America's No. 1 health problem in an upcoming 5-part series on PBS
Florida Times-Union (Jacksonville, FL), March 24, 1998 Tuesday,, City Edition, 1614 words, Nancy McAlister, Times-Union television writer
37. Treating addicts makes more sense
Morning Star (Wilmington, NC), March 19, 1998, Thursday, 422 words
38. PHYSICIANS URGE HELP FOR ADDICTS GROUP SAYS MEDICAL CARE FOR DRUG USERS COSTS LESS THAN PRISON. LONG-TERM TREATMENT IS CALLED EFFECTIVE.
Akron Beacon Journal (Ohio), March 18, 1998 Wednesday 1 STAR EDITION, NATION; Pg. A1, 1044 words, Raja Mishra, Knight Ridder Newspapers, The Associated, Press contributed to this report.
39. PUBLIC HEALTH: DOCTORS ARGUE DRUG ABUSE IS A DISEASE
American Health Line, March 18, 1998, ACCESS/QUALITY/COST, 926 words
40. Study: Treatment Best for Addicts
Associated Press Online, March 18, 1998; Wednesday, Washington - general news, 696 words, LAURAN NEERGAARD
41. MEDICAL SOLUTION FOR ADDICTION SEEN
The Commercial Appeal (Memphis, TN), March 18, 1998, WEDNESDAY,, 366 words, The Associated Press
42. Health Digest

Fort Worth Star-Telegram (Texas), March 18, 1998, Wednesday, 544 words, Wire Reports

43. DRUG ADDICTION JUST ANOTHER TREATABLE DISEASE, STUDY SAYS
Plain Dealer (Cleveland, Ohio), March 18, 1998 Wednesday, FINAL / ALL, NATIONAL;
Pg. 17A, 541 words, FROM STAFF AND WIRE REPORTS
44. Doctors push care, not prison, for drug addicts
USA TODAY, March 18, 1998, Wednesday, 480 words, Steve Sternberg
45. Medical leaders come out in favor of treatment for drug users instead of punishment
Knight Ridder Washington Bureau, March 17, 1998, Tuesday, WASHINGTON, 911
words, By Raja Mishra
46. Medical training faulted in substance-abuse cases; A panel headed by a Brown University
professor says medical schools should better prepare students to recognize and treat
alcoholism and drug abuse.
Providence Journal-Bulletin (Rhode Island), February 13, 1996, Tuesday, 406 words, C.
EUGENE EMERY JR.; Journal-Bulletin Science Writer
47. Slaves to substance abuse
Health Quest: The Publication of Black Wellness, January 31, 1994, Vol. 1; No. 3; Pg. 57,
1941 words, Green, Connie
48. SUBSTANCE ABUSE WAR NEEDED
Calgary Herald (Alberta, Canada), July 4, 1993, Sunday, FINAL EDITION, CITY & LIFE;
Pg. A4, 364 words, MARIO TONEGUZZI
49. PENN STUDY SHOWS DRAMATIC SUCCESS FOR MERCY DRUG AND ALCOHOL
REHAB PROGRAM
PR Newswire, October 15, 1992, Thursday, State and Regional News, 439 words
50. Drying out is just a start: alcoholism; includes related article
Medical World News, February 13, 1989, Pg. 56(7), 4180 words, Trubo, Richard
51. Drug Deaths and Pavlov's Dogs
The Washington Post, October 23, 1988, Sunday, Final Edition, OUTLOOK; PAGE C3;
OUTPOSTS, 2178 words, Richard Restak

13. Public Office, Political Activities and Affiliations:

- a. List chronologically any public offices you have held, other than judicial offices,
including the terms of service and whether such positions were elected or
appointed. If appointed, please include the name of the individual who appointed
you. Also, state chronologically any unsuccessful candidacies you have had for
elective office or unsuccessful nominations for appointed office.

None

- b. List all memberships and offices held in and services rendered, whether compensated or not, to any political party or election committee. If you have ever held a position or played a role in a political campaign, identify the particulars of the campaign, including the candidate, dates of the campaign, your title and responsibilities.

None

Legal Career: Answer each part separately. – **Not Applicable -**

14. **Litigation:** **Not Applicable- None:**

15. **Legal Activities:** **Not Applicable - None**

16. **Teaching:** What courses have you taught? For each course, state the title, the institution at which you taught the course, the years in which you taught the course, and describe briefly the subject matter of the course and the major topics taught. If you have a syllabus of each course, provide four (4) copies to the committee.

I do not have a syllabus from any course I have taught. The following are the classes I have taught with a brief synopsis of the course matter and topics.

University of Pennsylvania School of Medicine

- **Statistical Methods 301 – Introduction to statistics for physicians – 1980-1993**
This is an introductory course for third year medical students describing how to analyze research findings from research studies. Methods such as analysis of variance and covariance, linear and multiple regression, and multivariate logistic regression are discussed in the context of data from clinical trials
- **Graduate Seminars (for Fellows and Residents in Medicine) – 1987-2008**
All of those that follow are elective seminars for post graduate fellows in medicine and psychology.
 - Assessment and Measurement – 1987-2000** This is an advanced course on how to design and test clinical interviews and questionnaires used to assess patient problems at the beginning of treatment, during the course of care and at post treatment follow-up points. Issues of reliability and validity and Item Response Theory were discussed in

the context of data from existing instruments developed by my research group.

Treatment Outcome Evaluation Methods -2000-2008 This is an advanced course describing the methods for obtaining outcome information on patients with substance use and mental health illnesses; as well as how to analyze and interpret the findings from those evaluations. Methods were described in the context of actual evaluations done by my research group.

Graduate Topics in Addiction Treatment – 1998-2002 This is an elective course that is basically a team-taught seminar series presenting topics from the research done by faculty within the Psychiatry Department. My particular lectures had to do with patient assessment, outcome evaluation and instrument development.

17. **Deferred Income/ Future Benefits:** List the sources, amounts and dates of all anticipated receipts from deferred income arrangements, stock, options, uncompleted contracts and other future benefits which you expect to derive from previous business relationships, professional services, firm memberships, former employers, clients or customers. Describe the arrangements you have made to be compensated in the future for any financial or business interest.

I have resigned from the Treatment Research Institute (TRI) and will receive no further salary from the Institute. I will retain my existing TRI retirement account. I have requested a leave of absence from the University of Pennsylvania. I will receive no salary or benefits from the University during my tenure at ONDCP. I will retain my University of Pennsylvania retirement account. I have no deferred income or future benefits from any other business interests or professional services.

18. **Outside Commitments During Service:** Do you have any plans, commitments, or agreements to pursue outside employment, with or without compensation, during your service with the court? If so, explain.

I do not.

19. **Sources of Income:** List sources and amounts of all income received during the calendar year preceding your nomination and for the current calendar year, including all salaries, fees, dividends, interest, gifts, rents, royalties, licensing fees, honoraria, and other items exceeding \$500 or more (if you prefer to do so, copies of the financial disclosure report, required by the Ethics in Government Act of 1978, may be substituted here).

Please see my nomination public financial disclosure Standard Form 278.

20. **Statement of Net Worth:** Please complete the attached financial net worth statement in detail (add schedules as called for).

Please see attached Form.

21. Potential Conflicts of Interest:

- a. Identify the family members or other persons, parties, affiliations, pending and categories of litigation, financial arrangements or other factors that are likely to present potential conflicts-of-interest when you first assume the position to which you have been nominated. Explain how you would address any such conflict if it were to arise.

Through the course of the nomination process, I have consulted with the Office of Government Ethics and with the designated ethics official at the Office of National Drug Control Policy to identify potential conflicts of interest. Any potential conflicts of interest will be resolved in accordance with the terms of an ethics agreement that I have entered into with ONDCP's designated agency ethics official.

- b. Explain how you will resolve any potential conflict of interest, including the procedure you will follow in determining these areas of concern.

In connection with this nomination process, I have consulted with the Office of National Drug Control Policy's designated agency ethics official to identify potential conflicts of interest. Any potential conflicts of interest will be resolved in accordance with the terms of an ethics agreement that I have entered into with ONDCP's designated agency ethics official.

22. **Pro Bono Work:** An ethical consideration under Canon 2 of the American Bar Association's Code of Professional Responsibility calls for "every lawyer, regardless of professional prominence or professional workload, to find some time to participate in serving the disadvantaged." Describe what you have done to fulfill these responsibilities, listing specific instances and the amount of time devoted to each. If you are not an attorney, please use this opportunity to report significant charitable and volunteer work you may have done.

Please see Pro Bono Work section of Employment Record, question number 6.

FINANCIAL STATEMENT

NET WORTH

Provide a complete, current financial net worth statement which itemizes in detail all assets (including bank accounts, real estate, securities, trusts, investments, and other financial holdings) all liabilities (including debts, mortgages, loans, and other financial obligations) of yourself, your spouse, and other immediate members of your household.

ASSETS				LIABILITIES			
Cash on hand and in banks*		30	000	Notes payable to banks-secured			0
U.S. Government securities-add schedule			0	Notes payable to banks-unsecured			0
Listed securities-add schedule*		740	000	Notes payable to relatives			0
Unlisted securities--add schedule			0	Notes payable to others			0
Accounts and notes receivable:			0	Accounts and bills due			0
Due from relatives and friends			0	Unpaid income tax			0
Due from others			0	Other unpaid income and interest			0
Doubtful			0	Real estate mortgages payable-add schedule*		738	000
Real estate owned-add schedule*	1	355	000	Chattel mortgages and other liens payable			0
Real estate mortgages receivable			0	Other debts-itemize:			0
Autos and other personal property*		222	000				
Cash value-life insurance			0				
Other assets itemize:*							
Veterans Admin Thrift Savings		55	000				
				Total liabilities		738	000
				Net Worth		1 664	000
Total Assets		2 402	000	Total liabilities and net worth		2 402	000
CONTINGENT LIABILITIES				GENERAL INFORMATION			
As endorser, comaker or guarantor			0	Are any assets pledged? (Add schedule)			No
On leases or contracts			0	Are you defendant in any suits or legal actions?			No
Legal Claims			0	Have you ever taken bankruptcy?			No
Provision for Federal Income Tax			0				
Other special debt			0				

* See attached schedule

Schedule describing McLellan answers on Financial Statement for Non-Judicial Nominees

ASSETS

Cash on hand \$30,000
 Source is Carise Money market acct plus our checking accounts

Listed Securities (All IRA or 403B retirements)

U of Penn & TRI Vanguard Windsor	\$320,000
U of Penn & TRI TIAA (Trad)	\$182,500
U of Penn & TRI CREF (Stock)	\$182,500
TRI Vanguard Int. Val. Fund	\$6,000
TRI Vanguard Int. Health Fund	\$5,000
TRI Vanguard Int. Growth Fund	\$6,000
TRI Vanguard Health Care Fund	\$14,000
Personal Wachovia Retirement	\$24,000

Sources within Wachovia IRA - Open End Mutual Fund

Wells Fargo Adv End SL-I

Artio Gbl Intl Eq II I

DWS Inv Tr Core FXD CI I

Harbor Intl Fund

Pimco Total Return Instl

TCW Divers Val-I

Touchstn Snds CP Inst GR

Western Asset Core BD-I

Real Estate

[REDACTED]	\$675,000
[REDACTED]	\$680,000

Autos & Personal Property

2001 Porsche	\$22,000
2006 Audi	\$20,000
1987 Wilbur (34' Boat)	\$160,000
~15 paintings and some antique furniture	\$20,000

Other Assets

McLellan Vet. Admin. Thrift Saving	\$55,000
------------------------------------	----------

LIABILITIES

Real Estate Mortgages

Wells Fargo Home mortgage - Phila	\$275,000
Chase Home Mortgage - Ocean City	\$338,000
Chase Second Mortgage - Ocean City	\$125,000